JPH0466454B2 - - Google Patents
Info
- Publication number
- JPH0466454B2 JPH0466454B2 JP60501519A JP50151985A JPH0466454B2 JP H0466454 B2 JPH0466454 B2 JP H0466454B2 JP 60501519 A JP60501519 A JP 60501519A JP 50151985 A JP50151985 A JP 50151985A JP H0466454 B2 JPH0466454 B2 JP H0466454B2
- Authority
- JP
- Japan
- Prior art keywords
- recombinant
- protein
- sds
- hplc
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 108010002350 Interleukin-2 Proteins 0.000 description 94
- 102000000588 Interleukin-2 Human genes 0.000 description 94
- 239000000203 mixture Substances 0.000 description 29
- 235000018102 proteins Nutrition 0.000 description 28
- 108090000623 proteins and genes Proteins 0.000 description 28
- 102000004169 proteins and genes Human genes 0.000 description 28
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 19
- 239000000243 solution Substances 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 238000000605 extraction Methods 0.000 description 15
- 241000588724 Escherichia coli Species 0.000 description 14
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 14
- 238000004007 reversed phase HPLC Methods 0.000 description 14
- 235000018417 cysteine Nutrition 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 11
- 244000005700 microbiome Species 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 10
- 238000002523 gelfiltration Methods 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 8
- 229930195725 Mannitol Natural products 0.000 description 8
- 239000003638 chemical reducing agent Substances 0.000 description 8
- 239000000594 mannitol Substances 0.000 description 8
- 235000010355 mannitol Nutrition 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000009472 formulation Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000005063 solubilization Methods 0.000 description 7
- 230000007928 solubilization Effects 0.000 description 7
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000000356 contaminant Substances 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000003599 detergent Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 102000055277 human IL2 Human genes 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 239000007790 solid phase Substances 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 239000012062 aqueous buffer Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 229940090044 injection Drugs 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 230000005526 G1 to G0 transition Effects 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 239000008135 aqueous vehicle Substances 0.000 description 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 229960003067 cystine Drugs 0.000 description 3
- 238000011026 diafiltration Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000001641 gel filtration chromatography Methods 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 3
- 229940016590 sarkosyl Drugs 0.000 description 3
- 108700004121 sarkosyl Proteins 0.000 description 3
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 102000008072 Lymphokines Human genes 0.000 description 2
- 108010074338 Lymphokines Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- -1 alkali metal sarcosinate Chemical class 0.000 description 2
- 229910052936 alkali metal sulfate Inorganic materials 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000011210 chromatographic step Methods 0.000 description 2
- 229960003964 deoxycholic acid Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229960000789 guanidine hydrochloride Drugs 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- ZIHBOROHTYWINY-UHFFFAOYSA-N propan-1-ol;2,2,2-trifluoroacetic acid Chemical compound CCCO.OC(=O)C(F)(F)F ZIHBOROHTYWINY-UHFFFAOYSA-N 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N βâMercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 101100232904 Homo sapiens IL2 gene Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- 206010067737 Lupus hepatitis Diseases 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108010089814 Plant Lectins Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- GONSYFXEPMZGNN-UHFFFAOYSA-N acetic acid;propan-1-ol Chemical compound CCCO.CC(O)=O GONSYFXEPMZGNN-UHFFFAOYSA-N 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001820 anti-cytotoxin effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 150000001945 cysteines Chemical group 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000013541 low molecular weight contaminant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 235000006180 nutrition needs Nutrition 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- IFPHDUVGLXEIOQ-UHFFFAOYSA-N ortho-iodosylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1I=O IFPHDUVGLXEIOQ-UHFFFAOYSA-N 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 239000003726 plant lectin Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Description
è«æ±ã®ç¯å²
ïŒ ã€ã³ã¿ãŒãã€ãã³âïŒïŒILâïŒïŒã®æ²»çãã
ãããããã«æ£è ã«éçµè žæäžãããå»è¬ã補é
ããããã®ãå»è¬ãšããŠèš±å®¹ãããæ°Žæ§ããã¯ã«
äžã«åæ§æãããçµæILâïŒçµæç©ã§ãã€ãŠã (a) 58äœã®ã·ã¹ãã€ã³åã³105äœã®ã·ã¹ãã€ã³ã
éžæçã«é žåãããŠã·ã¹ãã³ã圢æãããããš
ã«ãã掻æ§åããã埮çç©çã«çç£ãããçµæ
ILâïŒã®å»ççæå¹éïŒ (b) åèšé žåããã埮çç©çã«çç£ãããILâ
ïŒã®å®å®æ§ã«äžéœåãªåœ±é¿ãäžããªãå»è¬ãšã
ãŠèš±å®¹ããã氎溶æ§æ äœïŒåã³ (c) åèšé žåããã埮çç©çã«çç£ãããILâ
ïŒã®æ°Žæº¶æ§ã確ä¿ããããã«ååãªéã®çé¢æŽ»
æ§å€ïŒ ãå«ãã§æãç¡èåçµä¹Ÿç¥æ··åç©ã§ããããšãç¹
城ãšããçµæç©ã
ãããããã«æ£è ã«éçµè žæäžãããå»è¬ã補é
ããããã®ãå»è¬ãšããŠèš±å®¹ãããæ°Žæ§ããã¯ã«
äžã«åæ§æãããçµæILâïŒçµæç©ã§ãã€ãŠã (a) 58äœã®ã·ã¹ãã€ã³åã³105äœã®ã·ã¹ãã€ã³ã
éžæçã«é žåãããŠã·ã¹ãã³ã圢æãããããš
ã«ãã掻æ§åããã埮çç©çã«çç£ãããçµæ
ILâïŒã®å»ççæå¹éïŒ (b) åèšé žåããã埮çç©çã«çç£ãããILâ
ïŒã®å®å®æ§ã«äžéœåãªåœ±é¿ãäžããªãå»è¬ãšã
ãŠèš±å®¹ããã氎溶æ§æ äœïŒåã³ (c) åèšé žåããã埮çç©çã«çç£ãããILâ
ïŒã®æ°Žæº¶æ§ã確ä¿ããããã«ååãªéã®çé¢æŽ»
æ§å€ïŒ ãå«ãã§æãç¡èåçµä¹Ÿç¥æ··åç©ã§ããããšãç¹
城ãšããçµæç©ã
ïŒ åèšé
žåããã埮çç©çã«çç£ãããILâ
ïŒäžã®éâILâïŒèçœè³ªã®å«éãïŒééïŒ æªæº
ã§ããããããŠåèšçé¢æŽ»æ§å€ãããã·ã«ç¡«é žã
ããªãŠã ïŒSDSïŒåã¯ããªãã·ã³ãŒã«é žãããªãŠ
ã ã§ããããšãç¹åŸŽãšããè«æ±ã®ç¯å²ç¬¬ïŒé èšèŒ
ã®çµæç©ã
ïŒäžã®éâILâïŒèçœè³ªã®å«éãïŒééïŒ æªæº
ã§ããããããŠåèšçé¢æŽ»æ§å€ãããã·ã«ç¡«é žã
ããªãŠã ïŒSDSïŒåã¯ããªãã·ã³ãŒã«é žãããªãŠ
ã ã§ããããšãç¹åŸŽãšããè«æ±ã®ç¯å²ç¬¬ïŒé èšèŒ
ã®çµæç©ã
ïŒ åèšããã·ã«ç¡«é
žãããªãŠã ãïŒmgã®ILâ
ïŒåœã100ã250ÎŒïœååšããããšãç¹åŸŽãšããè«
æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®çµæç©ã
ïŒåœã100ã250ÎŒïœååšããããšãç¹åŸŽãšããè«
æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®çµæç©ã
ïŒ åèšéžæçã«é
žåããã埮çç©çã«çç£ãã
ãçµæILâïŒãæ··åç©ã®0.02ééïŒ ã3.85ééïŒ
ãå ããããšãç¹åŸŽãšããè«æ±ã®ç¯å²ç¬¬ïŒé ã第
ïŒé ã®ããããïŒé ã«èšèŒã®çµæç©ã
ãçµæILâïŒãæ··åç©ã®0.02ééïŒ ã3.85ééïŒ
ãå ããããšãç¹åŸŽãšããè«æ±ã®ç¯å²ç¬¬ïŒé ã第
ïŒé ã®ããããïŒé ã«èšèŒã®çµæç©ã
ïŒ åèšçµç¹ILâïŒãdesâalalLâ2ser125ã§ã
ãããããŠåèšæ°Žæº¶æ§æ äœããã³ãããŒã«ã§ãã
ããšãç¹åŸŽãšããè«æ±ã®ç¯å²ç¬¬ïŒé ã第ïŒé ã®ã
ãããïŒé ã«èšèŒã®çµæç©ã
ãããããŠåèšæ°Žæº¶æ§æ äœããã³ãããŒã«ã§ãã
ããšãç¹åŸŽãšããè«æ±ã®ç¯å²ç¬¬ïŒé ã第ïŒé ã®ã
ãããïŒé ã«èšèŒã®çµæç©ã
æ现æž
ãã®çºæã¯å»è¬ã®åéã«é¢ãããããã«è©³ãã
ã¯ãããã¯åŸ®çç©çã«è£œé ãããã€ã³ã¿ãŒãã€ã
ã³âïŒã®å»è¬è£œå€ã«é¢ããã
ã¯ãããã¯åŸ®çç©çã«è£œé ãããã€ã³ã¿ãŒãã€ã
ã³âïŒã®å»è¬è£œå€ã«é¢ããã
ã€ã³ã¿ãŒãã€ãã³âïŒãããªãã¡æ£åžžãªæ«æ¢¢è¡
ãªã³ãçã«ããçç£ããããããŠæ€ç©ã¬ã¯ãã³ã
æåãåã¯ä»ã®åºæ¿ç©è³ªã«æŽé²ãããåŸæååã¯
ãã€ããžãšã³ã§åºæ¿ããã现èã®å¢æ®ãèªå°ã
ããªã³ãã«ã€ã³ã¯ãMorganãD.AçãSciense
ïŒ1976ïŒ193ïŒ1007â1008ã«ããæåã«èšèŒãã
ãããããŠãåºæ¿ããããªã³ãçã®å¢æ®ãèªå°
ãããã®èœåã®ããã«ïŒŽçŽ°èå¢æ®å åãšåŒã°ãã
ããä»ããã®å¢æ®å åæ§ã«å ããŠããã®ãã®ã¯ã€
ã³âãããåã³ã€ã³âããã§å ç«ç³»çŽ°èã®çš®ã ã®
æ©èœã調ç¯ããããšãèªèããããããŠã€ã³ã¿ãŒ
ãã€ãã³âïŒïŒILâïŒïŒãšç§°ãããŠãããILâïŒ
ã¯ãå ç«çŽ°èã®çžäºäœçšåã³æ©èœãäžä»ããããª
ã³ãçã«ããçç£ããã幟ã€ãã®ã¡ãã»ã³ãžã€ãŒ
âå¶åŸ¡ååã®ïŒã€ã§ããã
ãªã³ãçã«ããçç£ããããããŠæ€ç©ã¬ã¯ãã³ã
æåãåã¯ä»ã®åºæ¿ç©è³ªã«æŽé²ãããåŸæååã¯
ãã€ããžãšã³ã§åºæ¿ããã现èã®å¢æ®ãèªå°ã
ããªã³ãã«ã€ã³ã¯ãMorganãD.AçãSciense
ïŒ1976ïŒ193ïŒ1007â1008ã«ããæåã«èšèŒãã
ãããããŠãåºæ¿ããããªã³ãçã®å¢æ®ãèªå°
ãããã®èœåã®ããã«ïŒŽçŽ°èå¢æ®å åãšåŒã°ãã
ããä»ããã®å¢æ®å åæ§ã«å ããŠããã®ãã®ã¯ã€
ã³âãããåã³ã€ã³âããã§å ç«ç³»çŽ°èã®çš®ã ã®
æ©èœã調ç¯ããããšãèªèããããããŠã€ã³ã¿ãŒ
ãã€ãã³âïŒïŒILâïŒïŒãšç§°ãããŠãããILâïŒ
ã¯ãå ç«çŽ°èã®çžäºäœçšåã³æ©èœãäžä»ããããª
ã³ãçã«ããçç£ããã幟ã€ãã®ã¡ãã»ã³ãžã€ãŒ
âå¶åŸ¡ååã®ïŒã€ã§ããã
ILâïŒã¯æåããæ«æ¢¢è¡ãªã³ãçïŒPBLïŒå
ã¯ä»ã®ILâïŒçç£æ§ã»ã«ã©ã€ã³ãå¹é€ããããš
ã«ããäœããããäŸãã°ãç±³åœç¹èš±No.4401756ã
åç §ã®ããšãçµæDNAææ³ã¯PBLåã³ILâïŒç
ç£ã»ã«ã©ã€ã³ã®ä»£æ¿ç©ãæäŸãããã¿ãã°ãã
T.çãNatureïŒ1983ïŒ302ïŒ305â310ãåã³
DevosãR.ãNucleic Acids ResearchïŒ1983ïŒ
11ïŒ4307â4323ã¯ããILâïŒéºäŒåã®ã¯ããŒã
ã³ã°åã³åŸ®çç©äžã§ã®ãã®çºçŸãå ±åããã
ã¯ä»ã®ILâïŒçç£æ§ã»ã«ã©ã€ã³ãå¹é€ããããš
ã«ããäœããããäŸãã°ãç±³åœç¹èš±No.4401756ã
åç §ã®ããšãçµæDNAææ³ã¯PBLåã³ILâïŒç
ç£ã»ã«ã©ã€ã³ã®ä»£æ¿ç©ãæäŸãããã¿ãã°ãã
T.çãNatureïŒ1983ïŒ302ïŒ305â310ãåã³
DevosãR.ãNucleic Acids ResearchïŒ1983ïŒ
11ïŒ4307â4323ã¯ããILâïŒéºäŒåã®ã¯ããŒã
ã³ã°åã³åŸ®çç©äžã§ã®ãã®çºçŸãå ±åããã
1983幎11æ14æ¥ã«èš±å¯ããããã«ã®ãŒç¹èš±No.
898016ã¯ãéçååã¯å€©ç¶ååã®125äœã«éåžžå
åšããã·ã¹ãã€ã³ãé€å»ããåã¯ã»ãªã³ã®ããšã
äžæ§ã¢ããé žã«ãã眮ãå€ããããŠããILâïŒ
ã®ã ãã€ã³ãèšèŒããŠããããããã®ã ãã€ã³ã¯
ILâïŒçç©æŽ»æ§ãæããããã®ãã«ã®ãŒç¹èš±ã¯ã
該çµæã ãã€ã³ãããããæ°Žæ§ããã¯ã«ãšæ··å
ãããããŠéèå ãç®äžçã«æ³šå°ããããšã«ãã
倩ç¶ILâïŒãšåæ§ã«è£œå€åãããããŠæäžãã
åŸãããšãèšèŒããŠããã
898016ã¯ãéçååã¯å€©ç¶ååã®125äœã«éåžžå
åšããã·ã¹ãã€ã³ãé€å»ããåã¯ã»ãªã³ã®ããšã
äžæ§ã¢ããé žã«ãã眮ãå€ããããŠããILâïŒ
ã®ã ãã€ã³ãèšèŒããŠããããããã®ã ãã€ã³ã¯
ILâïŒçç©æŽ»æ§ãæããããã®ãã«ã®ãŒç¹èš±ã¯ã
該çµæã ãã€ã³ãããããæ°Žæ§ããã¯ã«ãšæ··å
ãããããŠéèå ãç®äžçã«æ³šå°ããããšã«ãã
倩ç¶ILâïŒãšåæ§ã«è£œå€åãããããŠæäžãã
åŸãããšãèšèŒããŠããã
ãã®çºæã®ïŒã€ã®èŠ³ç¹ã¯ãILâïŒçæ³ããã
ããããã«æ£è ã«éçµè žçã«æäžããããã«å»è¬
ãšããŠèš±å®¹ãããæ°Žæ§ããã¯ã«äžã«åæ§æ
ïŒreconstituteïŒããããšãã§ããILâïŒçµæç©
ã«é¢ãããã®çµæç©ã¯ïŒ (a) éâILâïŒèçœè³ªãå®è³ªçã«å«æããªãé ž
åããã埮çç©å ã«çç£ãããçµæILâïŒã®
å»ççã«æå¹ãªéïŒ (b) 該埮çç©ã«çç£ãããILâïŒã®å®å®æ§ã«äž
éœåãªåœ±é¿ãäžããªãå»è¬ãšããŠèš±èŠãããæ°Ž
溶æ§æ äœïŒåã³ã (c) åèšåŸ®çç©çã«çç£ãããçµæILâïŒã®æ°Ž
溶æ§ã確ä¿ããã®ã«ååãªéã®çé¢æŽ»æ§å€ãäŸ
ãã°ã¢ã«ã«ãªéå±ç¡«é žå¡©ãäŸãã°ããã·ã«ç¡«é ž
ãããªãŠã ïŒSDSïŒãã¢ã«ã«ãªéå±ãµã«ã³ã·ã
ãŒããåã¯ããªãã·ã³ãŒã«é žãããªãŠã ïŒ ãå«ãã§æãã
ããããã«æ£è ã«éçµè žçã«æäžããããã«å»è¬
ãšããŠèš±å®¹ãããæ°Žæ§ããã¯ã«äžã«åæ§æ
ïŒreconstituteïŒããããšãã§ããILâïŒçµæç©
ã«é¢ãããã®çµæç©ã¯ïŒ (a) éâILâïŒèçœè³ªãå®è³ªçã«å«æããªãé ž
åããã埮çç©å ã«çç£ãããçµæILâïŒã®
å»ççã«æå¹ãªéïŒ (b) 該埮çç©ã«çç£ãããILâïŒã®å®å®æ§ã«äž
éœåãªåœ±é¿ãäžããªãå»è¬ãšããŠèš±èŠãããæ°Ž
溶æ§æ äœïŒåã³ã (c) åèšåŸ®çç©çã«çç£ãããçµæILâïŒã®æ°Ž
溶æ§ã確ä¿ããã®ã«ååãªéã®çé¢æŽ»æ§å€ãäŸ
ãã°ã¢ã«ã«ãªéå±ç¡«é žå¡©ãäŸãã°ããã·ã«ç¡«é ž
ãããªãŠã ïŒSDSïŒãã¢ã«ã«ãªéå±ãµã«ã³ã·ã
ãŒããåã¯ããªãã·ã³ãŒã«é žãããªãŠã ïŒ ãå«ãã§æãã
奜ãŸããã¯ãçµæILâïŒãéžæçã«é
žåããã
ååãçç©çã«æŽ»æ§ã§ããããã«58äœåã³105äœ
ã®ã·ã¹ãã€ã³ããžã¹ã«ãã€ãçµåã圢æããã
ååãçç©çã«æŽ»æ§ã§ããããã«58äœåã³105äœ
ã®ã·ã¹ãã€ã³ããžã¹ã«ãã€ãçµåã圢æããã
ãã®çºæã®ä»ã®èŠ³ç¹ã¯æ£è
ã«æ²»çãããããå»
è¬çµæç©ã§ããããã®çµæç©ã¯ïŒ (a) äžèšã®æ··åç©ãšïŒ (b) 該混åç©ã溶解ããŠããå»è¬ãšããŠèš±å®¹ãã
ãæ°Žæ§éåŸè žããã¯ã«ïŒ ãå«ãã§æãããã®æº¶æ¶²ã¯mlåœãçŽ0.01mgãçŽïŒ
mgã®ç¯å²ã®åŸ®çç©çã«çç£ãããçµæILâïŒã
å«æããã
è¬çµæç©ã§ããããã®çµæç©ã¯ïŒ (a) äžèšã®æ··åç©ãšïŒ (b) 該混åç©ã溶解ããŠããå»è¬ãšããŠèš±å®¹ãã
ãæ°Žæ§éåŸè žããã¯ã«ïŒ ãå«ãã§æãããã®æº¶æ¶²ã¯mlåœãçŽ0.01mgãçŽïŒ
mgã®ç¯å²ã®åŸ®çç©çã«çç£ãããçµæILâïŒã
å«æããã
第ïŒå³ã¯ã埮çç©çã«çç£ãããçµæILâïŒ
ãåŠçããããŠç²Ÿè£œããããã®å¥œãŸããæ¹æ³ã®æµ
ãå³ã§ããã
ãåŠçããããŠç²Ÿè£œããããã®å¥œãŸããæ¹æ³ã®æµ
ãå³ã§ããã
ããã§ã䜿çšããå ŽåãâILâïŒâãªãèªã¯ã
(a)58äœåã³105äœã®ã·ã¹ãã€ã³ã®ãžã¹ã«ãã€ãçµ
åãå«ã倩ç¶ããã€ã³ã¿ãŒãã€ãã³âïŒã®ã¢ãã
é žé åãšå°ãªããšãå®è³ªçã«åäžãªã¢ããé žé å
ãæãããããŠ(b)倩ç¶ããâã€ã³ã¿ãŒãã€ãã³â
ïŒãšå ±éã®çç©åŠç掻æ§ãæããèçœè³ªãã³ãŒã
ããããã€ã³ã¿ãŒãã€ãã³â2DNAé ååã¯è©²ã
ãâã€ã³ã¿ãŒãã€ãã³â2DNAé åã®å€åœ¢ç©ã«ã
ã圢質転æããã埮çç©ã«ããçç£ãããéã°ãª
ã³ã·ã«åèçœè³ªãæå³ãããã¢ããé žé åã®å®è³ª
äžåäžãšã¯ãé åãåäžã§ãããããããã¯åæ
èçœè³ªãšå€©ç¶ããâã€ã³ã¿ãŒãã€ãã³âïŒãšã®é
ã®äžéœåãªæ©èœçéé¡äŒŒæ§ãæ¹èµ·ããªãïŒååã¯
ããããå€ãã®ã¢ããé žã®å€åïŒæ¬ 倱ãä»å ã眮
æïŒã«ããç°ãªãããšãæå³ããããã®ãããªè
çœè³ªã®äŸã¯ã1983幎ïŒæïŒæ¥ã«åºé¡ããããšãŒã
ããç¹èš±åºé¡No.83101035.0ïŒ1983幎10æ19æ¥å ¬é
No.91539ïŒãåã³1982幎12æ22æ¥ã«åºé¡ããããšãŒ
ãããç¹èš±åºé¡No.82307036.2ïŒ1983幎ïŒæ14æ¥å ¬
éNo.88195ïŒã«èšèŒãããŠããçµæILâïŒïŒãã«
ã®ãŒç¹èš±No.893.016ã«å¯Ÿå¿ãã1983幎10æ13æ¥ã«
åºé¡ããããšãŒãããç¹èš±åºé¡No.83306221.9
ïŒ1984幎ïŒæ30æ¥å ¬éNo.109748ïŒã«èšèŒãããŠã
ãçµçµILâïŒã ãã€ã³ïŒäžŠã³ã«ãã®åºé¡ã«èšèŒ
ãããŠããçµæILâïŒã§ããã
(a)58äœåã³105äœã®ã·ã¹ãã€ã³ã®ãžã¹ã«ãã€ãçµ
åãå«ã倩ç¶ããã€ã³ã¿ãŒãã€ãã³âïŒã®ã¢ãã
é žé åãšå°ãªããšãå®è³ªçã«åäžãªã¢ããé žé å
ãæãããããŠ(b)倩ç¶ããâã€ã³ã¿ãŒãã€ãã³â
ïŒãšå ±éã®çç©åŠç掻æ§ãæããèçœè³ªãã³ãŒã
ããããã€ã³ã¿ãŒãã€ãã³â2DNAé ååã¯è©²ã
ãâã€ã³ã¿ãŒãã€ãã³â2DNAé åã®å€åœ¢ç©ã«ã
ã圢質転æããã埮çç©ã«ããçç£ãããéã°ãª
ã³ã·ã«åèçœè³ªãæå³ãããã¢ããé žé åã®å®è³ª
äžåäžãšã¯ãé åãåäžã§ãããããããã¯åæ
èçœè³ªãšå€©ç¶ããâã€ã³ã¿ãŒãã€ãã³âïŒãšã®é
ã®äžéœåãªæ©èœçéé¡äŒŒæ§ãæ¹èµ·ããªãïŒååã¯
ããããå€ãã®ã¢ããé žã®å€åïŒæ¬ 倱ãä»å ã眮
æïŒã«ããç°ãªãããšãæå³ããããã®ãããªè
çœè³ªã®äŸã¯ã1983幎ïŒæïŒæ¥ã«åºé¡ããããšãŒã
ããç¹èš±åºé¡No.83101035.0ïŒ1983幎10æ19æ¥å ¬é
No.91539ïŒãåã³1982幎12æ22æ¥ã«åºé¡ããããšãŒ
ãããç¹èš±åºé¡No.82307036.2ïŒ1983幎ïŒæ14æ¥å ¬
éNo.88195ïŒã«èšèŒãããŠããçµæILâïŒïŒãã«
ã®ãŒç¹èš±No.893.016ã«å¯Ÿå¿ãã1983幎10æ13æ¥ã«
åºé¡ããããšãŒãããç¹èš±åºé¡No.83306221.9
ïŒ1984幎ïŒæ30æ¥å ¬éNo.109748ïŒã«èšèŒãããŠã
ãçµçµILâïŒã ãã€ã³ïŒäžŠã³ã«ãã®åºé¡ã«èšèŒ
ãããŠããçµæILâïŒã§ããã
ããã§äœ¿çšããå Žåãâ圢質転æããã埮çç©â
ãªãèªã¯ã倩ç¶ããâã€ã³ã¿ãŒãã€ãã³âïŒæŽ»æ§
ãæããèçœè³ªãçç£ããããã«éºäŒåæäœãã
ãŠãã埮çç©ãæå³ããã圢質転æããã埮çç©
ã®äŸã¯åèšãšãŒãããç¹èš±åºé¡å ¬éNo.88198ãNo.
91539ãåã³No.109748ã«èšèŒãããŠãããILâïŒ
ãçç£ããããã«çŽ°èã奜ãŸããããã®çºæã«ã
ããŠæçšãªå žåçãªåœ¢è³ªè»¢æããã埮çç©ã¯ãã
ã©ã¹ããpLWIã«ãã圢質転æãããE.ã³ãªïŒE.
coliïŒïŒ«â12æ ªMM294ïŒ1983幎ïŒæïŒæ¥ã«ã·ã¹
ã¿ã»ã³ãŒãã¬ãŒã·ãšã³ã«ãããã¿ãã¹ãæ¡çŽã®èŠ
å®ã®ããšã«ã¢ã¡ãªã«ã³ã»ã¿ã€ãã»ã«ã«ããŠã¢ãŒã»
ã³ã¬ã¯ã·ãšã³ã«å¯èšãããŠããããããŠåèšçªå·
39405ãæããïŒã§ãããåæçµæILâïŒã¯ãŸ
ããé©åã«åœ¢è³ªè»¢æãããé µæ¯åã³åºä¹³åç©çŽ°è
ã«ãã€ãŠãçç£ããåŸããE.ã³ãªãç¹ã«å¥œãŸãã
宿䞻çç©ã§ããã
ãªãèªã¯ã倩ç¶ããâã€ã³ã¿ãŒãã€ãã³âïŒæŽ»æ§
ãæããèçœè³ªãçç£ããããã«éºäŒåæäœãã
ãŠãã埮çç©ãæå³ããã圢質転æããã埮çç©
ã®äŸã¯åèšãšãŒãããç¹èš±åºé¡å ¬éNo.88198ãNo.
91539ãåã³No.109748ã«èšèŒãããŠãããILâïŒ
ãçç£ããããã«çŽ°èã奜ãŸããããã®çºæã«ã
ããŠæçšãªå žåçãªåœ¢è³ªè»¢æããã埮çç©ã¯ãã
ã©ã¹ããpLWIã«ãã圢質転æãããE.ã³ãªïŒE.
coliïŒïŒ«â12æ ªMM294ïŒ1983幎ïŒæïŒæ¥ã«ã·ã¹
ã¿ã»ã³ãŒãã¬ãŒã·ãšã³ã«ãããã¿ãã¹ãæ¡çŽã®èŠ
å®ã®ããšã«ã¢ã¡ãªã«ã³ã»ã¿ã€ãã»ã«ã«ããŠã¢ãŒã»
ã³ã¬ã¯ã·ãšã³ã«å¯èšãããŠããããããŠåèšçªå·
39405ãæããïŒã§ãããåæçµæILâïŒã¯ãŸ
ããé©åã«åœ¢è³ªè»¢æãããé µæ¯åã³åºä¹³åç©çŽ°è
ã«ãã€ãŠãçç£ããåŸããE.ã³ãªãç¹ã«å¥œãŸãã
宿䞻çç©ã§ããã
圢質転æããã埮çç©ããé©åœãªå¢æ®å¹å°äž
ã§ãå žåçã«ã¯680nïœã«ãŠå°ãªããšãçŽ30ãã
ããŠå¥œãŸããã¯680nïœã«ãããŠçŽ20ãçŽ40ã®å
åŠæ¿åºŠã«å¢æ®ãããããå¢æ®å¹å°ã®çµæã¯é¢äžã
ãç¹å®ã®åŸ®çç©ã«äŸåããã§ããããå¹å°ã¯ã埮
çç©ã®æ é€çèŠæ±ãæºããååç©ãå«æããæ°Žæ§
å¹å°ã§ãããå¢æ®å¹å°ã¯å žåçã«ã¯è³åæ§ã®ççŽ
åã³çªçŽ æºããšãã«ã®ãŒæºããã°ãã·ãŠã ãã«ãª
ãŠã åã³ãããªãŠã ã€ãªã³ã䞊ã³ã«å Žåã«ãã€ãŠ
ã¯ã¢ããé žãåã³ããªã³åã³ããªããžã³å¡©åºãå«
æããã§ãããããPrview of Medical
BiologyãLange Medical Publicationsã第14
ç80ã95é ïŒ1980ïŒãåç §ã®ããšããtrpãããŒã¢
ãŒã¿ãŒãçšããçºçŸãã¯ã¿ãŒã«ãããŠã¯ãå¹å°äž
ã®ããªãããã¢ã³æ¿åºŠããILâïŒçºçŸãæãŸã
ãæç¹ã§å¶éãããããã«æ³šææ·±ã調ç¯ãããã
E.ã³ãªã®ããã®å¢æ®å¹å°ã¯åœæ¥è ã«ãããŠããç¥
ãããŠããã奜ãŸããå¢æ®å¹å°ã¯1985幎ïŒæ12æ¥
ã«èš±å¯ãããç±³åœç¹èš±No.4499188ã«èšèŒãããŠã
ãã
ã§ãå žåçã«ã¯680nïœã«ãŠå°ãªããšãçŽ30ãã
ããŠå¥œãŸããã¯680nïœã«ãããŠçŽ20ãçŽ40ã®å
åŠæ¿åºŠã«å¢æ®ãããããå¢æ®å¹å°ã®çµæã¯é¢äžã
ãç¹å®ã®åŸ®çç©ã«äŸåããã§ããããå¹å°ã¯ã埮
çç©ã®æ é€çèŠæ±ãæºããååç©ãå«æããæ°Žæ§
å¹å°ã§ãããå¢æ®å¹å°ã¯å žåçã«ã¯è³åæ§ã®ççŽ
åã³çªçŽ æºããšãã«ã®ãŒæºããã°ãã·ãŠã ãã«ãª
ãŠã åã³ãããªãŠã ã€ãªã³ã䞊ã³ã«å Žåã«ãã€ãŠ
ã¯ã¢ããé žãåã³ããªã³åã³ããªããžã³å¡©åºãå«
æããã§ãããããPrview of Medical
BiologyãLange Medical Publicationsã第14
ç80ã95é ïŒ1980ïŒãåç §ã®ããšããtrpãããŒã¢
ãŒã¿ãŒãçšããçºçŸãã¯ã¿ãŒã«ãããŠã¯ãå¹å°äž
ã®ããªãããã¢ã³æ¿åºŠããILâïŒçºçŸãæãŸã
ãæç¹ã§å¶éãããããã«æ³šææ·±ã調ç¯ãããã
E.ã³ãªã®ããã®å¢æ®å¹å°ã¯åœæ¥è ã«ãããŠããç¥
ãããŠããã奜ãŸããå¢æ®å¹å°ã¯1985幎ïŒæ12æ¥
ã«èš±å¯ãããç±³åœç¹èš±No.4499188ã«èšèŒãããŠã
ãã
å¹é€ç©ãã现èãååŸããåŸãããããå¿
èŠã§
ããã°çŽ20ã500mgïŒmlã奜ãŸããã¯80ã100mgïŒ
mlïŒ680nïœã«ãããŠãOD40ã200ã奜ãŸããã¯
160ã200ïŒã«ãæ¿Ÿéãé å¿åé¢ãåã¯ä»ã®åžžæ³ã«
ããæ¿çž®ããã
ããã°çŽ20ã500mgïŒmlã奜ãŸããã¯80ã100mgïŒ
mlïŒ680nïœã«ãããŠãOD40ã200ã奜ãŸããã¯
160ã200ïŒã«ãæ¿Ÿéãé å¿åé¢ãåã¯ä»ã®åžžæ³ã«
ããæ¿çž®ããã
æ¿çž®ã«ç¶ãã埮çç©ã®çŽ°èèãç Žå£ããããã®
ç Žå£ã®äž»ããç®çã¯æ¬¡ã®æœåºåã³å¯æº¶å段éãä¿
é²ããããšã§ããããã®æ¹æ³ã®ãã®æ®µéã«ãããŠ
ã¯ãåžžçšã®çŽ°èç Žç ææ³ãäŸãã°ãã¢ãžãã€ãºã
è¶ é³æ³¢åŠçãåã¯å å§åŸªç°ã䜿çšããããšãã§ã
ãã奜ãŸããæ¹æ³ã¯ãã³ãã³âã¬ãŠãªã³
ïŒMantonâGaulinïŒãã¢ãžãã€ã¶ãŒãçšããè¶
é³æ³¢åŠçåã¯ãã¢ãžãã€ãºã§ãããç Žç 段éã®çµ
ç¹ã¯å åŠæ¿åºŠã«ããã¢ãã¿ãŒããããšãã§ããæž
æ¿æ¶²ã®å åŠæ¿åºŠãå žåçã«ã¯çŽ65ïŒ ã85ïŒ äœäžã
ãããããã«ããŠããç¡å·ã®çŽ°èãå¯æº¶å段éã«
æã¡èŸŒãŸããªãããã«å®è³ªäžãã¹ãŠã®çŽ°èãç Žå£
ãã¹ãã§ãããææã«ãããç Žç ã®åã«æ¿çž®ç©ã®
液çžã®PHãã次ã®æ®µéã«ãããŠãçµæILâïŒè
çœè³ªã现èç Žçäžã«äžæº¶æ§è€åäœãšããŠæ®ããªã
ãE.ã³ãªèçœè³ªã®é€å»ãä¿é²ããã¬ãã«ã«èª¿æŽã
ããPHã¯é©åœãªç·©è¡æ¶²ãæ·»å ããããšã«ãã€ãŠã
ã®ããã«èª¿æŽããããšãã§ãããã»ãšãã©ã®å Ž
åãçŽïŒãçŽ8.5ã®ç¯å²ã®PHã䜿çšããããã
ç Žå£ã®äž»ããç®çã¯æ¬¡ã®æœåºåã³å¯æº¶å段éãä¿
é²ããããšã§ããããã®æ¹æ³ã®ãã®æ®µéã«ãããŠ
ã¯ãåžžçšã®çŽ°èç Žç ææ³ãäŸãã°ãã¢ãžãã€ãºã
è¶ é³æ³¢åŠçãåã¯å å§åŸªç°ã䜿çšããããšãã§ã
ãã奜ãŸããæ¹æ³ã¯ãã³ãã³âã¬ãŠãªã³
ïŒMantonâGaulinïŒãã¢ãžãã€ã¶ãŒãçšããè¶
é³æ³¢åŠçåã¯ãã¢ãžãã€ãºã§ãããç Žç 段éã®çµ
ç¹ã¯å åŠæ¿åºŠã«ããã¢ãã¿ãŒããããšãã§ããæž
æ¿æ¶²ã®å åŠæ¿åºŠãå žåçã«ã¯çŽ65ïŒ ã85ïŒ äœäžã
ãããããã«ããŠããç¡å·ã®çŽ°èãå¯æº¶å段éã«
æã¡èŸŒãŸããªãããã«å®è³ªäžãã¹ãŠã®çŽ°èãç Žå£
ãã¹ãã§ãããææã«ãããç Žç ã®åã«æ¿çž®ç©ã®
液çžã®PHãã次ã®æ®µéã«ãããŠãçµæILâïŒè
çœè³ªã现èç Žçäžã«äžæº¶æ§è€åäœãšããŠæ®ããªã
ãE.ã³ãªèçœè³ªã®é€å»ãä¿é²ããã¬ãã«ã«èª¿æŽã
ããPHã¯é©åœãªç·©è¡æ¶²ãæ·»å ããããšã«ãã€ãŠã
ã®ããã«èª¿æŽããããšãã§ãããã»ãšãã©ã®å Ž
åãçŽïŒãçŽ8.5ã®ç¯å²ã®PHã䜿çšããããã
第ïŒå³ã«ç€ºãããã«ãç Žç 段éã«ç¶ãååå·¥çš
ã®æ®µéã¯ãILâïŒã®éå ç¶æ ã«ç¶æããªããè¯
奜ãªåçã§ãé«ã¬ãã«ã®çŽåºŠïŒå¥œãŸããã¯çŽ95ïŒ
以äžããããŠããã«å¥œãŸããã¯çŽ98ïŒ ä»¥äžïŒã«ã
E.ã³ãªèçœè³ªããILâïŒãåé¢ããããã«äž»ãšã
ãŠèšèšããããåæã«ããããã®ç²Ÿè£œå·¥çšã¯ãã
ã«ãçžãŸã€ãŠãæçµçæç©äžã«çºç±ç©è³ªããæ£è
ã«éåŸè žçã«æäžããããã«èš±å®¹ããããšä¿¡ãã
ããã¬ãã«ã«äœäžããããã
ã®æ®µéã¯ãILâïŒã®éå ç¶æ ã«ç¶æããªããè¯
奜ãªåçã§ãé«ã¬ãã«ã®çŽåºŠïŒå¥œãŸããã¯çŽ95ïŒ
以äžããããŠããã«å¥œãŸããã¯çŽ98ïŒ ä»¥äžïŒã«ã
E.ã³ãªèçœè³ªããILâïŒãåé¢ããããã«äž»ãšã
ãŠèšèšããããåæã«ããããã®ç²Ÿè£œå·¥çšã¯ãã
ã«ãçžãŸã€ãŠãæçµçæç©äžã«çºç±ç©è³ªããæ£è
ã«éåŸè žçã«æäžããããã«èš±å®¹ããããšä¿¡ãã
ããã¬ãã«ã«äœäžããããã
现èãç Žç ããåŸãç Žç ç©ã®æ¶²çžããç²ç¶ç©ã
åé¢ãããããŠæœåºã®ããã®æé©PHã«ç·©è¡åãã
ãæ°Žæ§åªäœäžã«åæžæ¿ããããšãã§ãããå Žåã«
ãã€ãŠã¯ç²ç¶ç©ããã®æ®µéã§ç·©è¡æ¶²ã«ããæŽæµã
ãŠãã®äžã®æ°Žææ§E.ã³ãªèçœè³ªãé€å»ããããšã
ã§ããããšããããæœåºã«ããããã现èæžæ¿äž
ã®èçœè³ªæ¿åºŠã¯éåžžçŽïŒãçŽ60mgïŒmlã奜ãŸãã
ã¯20ã40mgïŒmlã®ç¯å²ã§ããã
åé¢ãããããŠæœåºã®ããã®æé©PHã«ç·©è¡åãã
ãæ°Žæ§åªäœäžã«åæžæ¿ããããšãã§ãããå Žåã«
ãã€ãŠã¯ç²ç¶ç©ããã®æ®µéã§ç·©è¡æ¶²ã«ããæŽæµã
ãŠãã®äžã®æ°Žææ§E.ã³ãªèçœè³ªãé€å»ããããšã
ã§ããããšããããæœåºã«ããããã现èæžæ¿äž
ã®èçœè³ªæ¿åºŠã¯éåžžçŽïŒãçŽ60mgïŒmlã奜ãŸãã
ã¯20ã40mgïŒmlã®ç¯å²ã§ããã
ç²ç¶çŽ°èææããã®E.ã³ãªèçœè³ªã®æœåºã¯ãç Ž
ç ãšäº€äºã«ãåã¯ç Žç åŸã«ããã«ç¶ããŠè¡ãããš
ãã§ãããããã¯ã奜ãŸããã¯ç Žç ã«ç¶ã段éãš
ããŠè¡ããããæœåºå€ã¯ãã€ãªããããã¿å€
ïŒchaotropic agentïŒïŒããªãã¡ãæ°ŽçŽ çµåã解é¢
ãããããããŠèçœè³ªã®ïŒæ¬¡æ§é ã«åœ±é¿ãäžãã
ç·©åãªèçœè³ªå€æ§å€ïŒã®æ°Žæº¶æ¶²ã§ãããæœåºå€ã¯
现èç Žçããå€éã®E.ã³ãªèçœè³ªãéžæçã«é€å»
ãã现èç ŽçãšäŒåããŠããïŒå«æãããŠããã
åã¯çµåããŠããïŒçµæILâïŒã®å°ãªããšãå®
質çãªéšåãæ®ãããã®éžææ§ã¯ãçµæILâïŒ
ã®çæ°Žæ§ãåã³ãã®èçœè³ªã¯ãã®é»ç¹ã«è¿ãPHã«
ãããŠéå ãããäžæº¶æ§ã®ç¶æ ã«ãããšããäºå®
ã«ããä¿é²ããããããã«ãçµæILâïŒã®å®è³ª
çãªéšåã¯ãE.ã³ãªäžã§é«ã¬ãã«ã§çºçŸãããä»
ã®ã¯ããŒã³åèçœè³ªã®å Žåãšåæ§ã«ãææãªå€§ã
ãã®å°å ¥äœïŒinclusion bodyïŒãšããŠã€ã³âãã
ã«ååšããã§ããããæœåºå€ã®äŸã¯ãå°¿çŽ åã³å¡©
é žã°ã¢ããžã³ã§ããïŒå¯æº¶åå€ãšããŠSDSã䜿çš
ããå Žåãå¡©é žã°ã¢ããžã³ã䜿çšãã¹ãã§ãªãã
å°¿çŽ ã奜ãŸãããæœåºæ··åç©äžã®ãã€ãªãããã
ã¯å€ã®æ¿åºŠã¯äœ¿çšãããç¹å®ã®è¬å€åã³æœåºæ··å
ç©äžã®çŽ°èæ§ææã®éã«äŸåããã§ããããå°¿çŽ
ã®å ŽåãçŽ3.5Mã4.5Mã奜ãŸããã¯çŽ4Mã®æ¿
床ïŒæçµïŒã25âã«ãããååæ³ã«ãããŠäœ¿çšã
ããã§ããããæœåºãé·æéã«ããã€ãŠé£ç¶çã«
è¡ãããå Žåãäžå±€äœãæ¿åºŠãçšããã®ã奜ãŸã
ãã§ããããæœåºã«ãããŠã¯éåžž20âã25âã®ç¯
å²ã®æž©åºŠã䜿çšããã䟿å®äžå®€æž©ã䜿çšãããã§
ãããã溶液ãšç²ç¶ç©ãšã®éã®æ¥è§Šãå¢åŒ·ããã
ããŠããããããšã«ãã€ãŠçŽ°èç ŽçããéâIL
âïŒèçœè³ªãæœåºããããã«å¿ èŠãªæéãççž®ã
ãããã«ãæ··åãå žåçã«çšããããã§ãããã
SDSâPAGEãçšããŠãäžæž ã«ã€ããŠæœåºå·¥çšã®
é床åæãè¡ããããããŠ15ã30åéãŸã§ã«æœåº
ãæ¬è³ªäžå®çµããããšãèŠåºãããã
ç ãšäº€äºã«ãåã¯ç Žç åŸã«ããã«ç¶ããŠè¡ãããš
ãã§ãããããã¯ã奜ãŸããã¯ç Žç ã«ç¶ã段éãš
ããŠè¡ããããæœåºå€ã¯ãã€ãªããããã¿å€
ïŒchaotropic agentïŒïŒããªãã¡ãæ°ŽçŽ çµåã解é¢
ãããããããŠèçœè³ªã®ïŒæ¬¡æ§é ã«åœ±é¿ãäžãã
ç·©åãªèçœè³ªå€æ§å€ïŒã®æ°Žæº¶æ¶²ã§ãããæœåºå€ã¯
现èç Žçããå€éã®E.ã³ãªèçœè³ªãéžæçã«é€å»
ãã现èç ŽçãšäŒåããŠããïŒå«æãããŠããã
åã¯çµåããŠããïŒçµæILâïŒã®å°ãªããšãå®
質çãªéšåãæ®ãããã®éžææ§ã¯ãçµæILâïŒ
ã®çæ°Žæ§ãåã³ãã®èçœè³ªã¯ãã®é»ç¹ã«è¿ãPHã«
ãããŠéå ãããäžæº¶æ§ã®ç¶æ ã«ãããšããäºå®
ã«ããä¿é²ããããããã«ãçµæILâïŒã®å®è³ª
çãªéšåã¯ãE.ã³ãªäžã§é«ã¬ãã«ã§çºçŸãããä»
ã®ã¯ããŒã³åèçœè³ªã®å Žåãšåæ§ã«ãææãªå€§ã
ãã®å°å ¥äœïŒinclusion bodyïŒãšããŠã€ã³âãã
ã«ååšããã§ããããæœåºå€ã®äŸã¯ãå°¿çŽ åã³å¡©
é žã°ã¢ããžã³ã§ããïŒå¯æº¶åå€ãšããŠSDSã䜿çš
ããå Žåãå¡©é žã°ã¢ããžã³ã䜿çšãã¹ãã§ãªãã
å°¿çŽ ã奜ãŸãããæœåºæ··åç©äžã®ãã€ãªãããã
ã¯å€ã®æ¿åºŠã¯äœ¿çšãããç¹å®ã®è¬å€åã³æœåºæ··å
ç©äžã®çŽ°èæ§ææã®éã«äŸåããã§ããããå°¿çŽ
ã®å ŽåãçŽ3.5Mã4.5Mã奜ãŸããã¯çŽ4Mã®æ¿
床ïŒæçµïŒã25âã«ãããååæ³ã«ãããŠäœ¿çšã
ããã§ããããæœåºãé·æéã«ããã€ãŠé£ç¶çã«
è¡ãããå Žåãäžå±€äœãæ¿åºŠãçšããã®ã奜ãŸã
ãã§ããããæœåºã«ãããŠã¯éåžž20âã25âã®ç¯
å²ã®æž©åºŠã䜿çšããã䟿å®äžå®€æž©ã䜿çšãããã§
ãããã溶液ãšç²ç¶ç©ãšã®éã®æ¥è§Šãå¢åŒ·ããã
ããŠããããããšã«ãã€ãŠçŽ°èç ŽçããéâIL
âïŒèçœè³ªãæœåºããããã«å¿ èŠãªæéãççž®ã
ãããã«ãæ··åãå žåçã«çšããããã§ãããã
SDSâPAGEãçšããŠãäžæž ã«ã€ããŠæœåºå·¥çšã®
é床åæãè¡ããããããŠ15ã30åéãŸã§ã«æœåº
ãæ¬è³ªäžå®çµããããšãèŠåºãããã
æœåºã«ç¶ããæ··åç©ãåºçžãšæ¶²çžã«åé¢ããã
次ã«ãåºçžããéå å€åã³å¯æº¶åå€ãå«æããäž
æ§æ°Žæ§ç·©è¡æ¶²ãšæ¥è§Šããããããšã«ããåºçžäžã®
çµæILâïŒãå¯æº¶åãããçæ°Žæ§çµæILâïŒã
å¯æº¶åããããã«é©åãªçæ°Žæ§â芪氎æ§ãã©ã³ã¹
ãæããçççã«èš±å®¹ãããçé¢æŽ»æ§å€ïŒæŽå€ïŒ
ãçšããããšãã§ãããïŒã14åã®ççŽ ååãå«
æããã¢ã«ã«ãªéå±ç¡«é žå¡©åã³ã¢ã«ã«ãªéå±ã¢ã«
ãã«ãµã«ã³ã·ããŒãã奜ãŸããå¯æº¶åå€ã§ããã
SDSåã³ãµã«ã³ã·ã«ãç¹ã«å¥œãŸããã
次ã«ãåºçžããéå å€åã³å¯æº¶åå€ãå«æããäž
æ§æ°Žæ§ç·©è¡æ¶²ãšæ¥è§Šããããããšã«ããåºçžäžã®
çµæILâïŒãå¯æº¶åãããçæ°Žæ§çµæILâïŒã
å¯æº¶åããããã«é©åãªçæ°Žæ§â芪氎æ§ãã©ã³ã¹
ãæããçççã«èš±å®¹ãããçé¢æŽ»æ§å€ïŒæŽå€ïŒ
ãçšããããšãã§ãããïŒã14åã®ççŽ ååãå«
æããã¢ã«ã«ãªéå±ç¡«é žå¡©åã³ã¢ã«ã«ãªéå±ã¢ã«
ãã«ãµã«ã³ã·ããŒãã奜ãŸããå¯æº¶åå€ã§ããã
SDSåã³ãµã«ã³ã·ã«ãç¹ã«å¥œãŸããã
å¯æº¶åã«ãããŠäœ¿çšãããå溶åå€ã®éã¯ç¹å®
ã®è¬å€ã«äŸåããã§ããããSDSåã¯ãµã€ã³ã·ã«
ã䜿çšããå ŽåãSDSïŒãµã«ã³ã·ã«ãšåºçžèçœè³ª
ãšã®å¥œãŸããæ¯çïŒïŒ·ïŒïŒ·ïŒã¯çŽ0.5ïŒïŒã1.4ïŒ
ïŒã§ãããå¯æº¶åå€ã«ãŸããå¯æº¶åãããILâ
ïŒãææãªçšåºŠã«é žåãããã®ãé²æ¢ããããã«
ååãªéã®éå å€ãå«æãããèçœè³ªéå å€ãäŸ
ãã°ãžããªã¹ã¬ã€ããŒã«ïŒDTTïŒåã³ïŒâã¡ã«
ã«ãããšã¿ããŒã«ã䜿çšããããšãã§ããã
DTTã®ããšãéå å€ã®åªäœäžã§ã®æ¿åºŠã¯éåžžçŽ
ïŒã20mMã®ç¯å²ã§ããããå¯æº¶åã¯å žåçã«ã¯
20âã25âã®ç¯å²ã®æž©åºŠã«ãããŠãåºçžãšå¯æº¶å
åªäœãšã®éã®æ¥è§Šãä¿é²ããããã«æ··åããªãã
è¡ããäžå±€é«ã枩床ã¯äžææã®E.ã³ãªèçœè³ªãå¯
溶åããã§ãããããµã³ãã«ã15åé眮ããåã¯
溶液ãåéæã«ãªã€ãæã«å¯æº¶åãå®äºãããšè
ãããããå¯æº¶åã®å®äºåŸäžèŠç©ãåé¢ããã
ã®è¬å€ã«äŸåããã§ããããSDSåã¯ãµã€ã³ã·ã«
ã䜿çšããå ŽåãSDSïŒãµã«ã³ã·ã«ãšåºçžèçœè³ª
ãšã®å¥œãŸããæ¯çïŒïŒ·ïŒïŒ·ïŒã¯çŽ0.5ïŒïŒã1.4ïŒ
ïŒã§ãããå¯æº¶åå€ã«ãŸããå¯æº¶åãããILâ
ïŒãææãªçšåºŠã«é žåãããã®ãé²æ¢ããããã«
ååãªéã®éå å€ãå«æãããèçœè³ªéå å€ãäŸ
ãã°ãžããªã¹ã¬ã€ããŒã«ïŒDTTïŒåã³ïŒâã¡ã«
ã«ãããšã¿ããŒã«ã䜿çšããããšãã§ããã
DTTã®ããšãéå å€ã®åªäœäžã§ã®æ¿åºŠã¯éåžžçŽ
ïŒã20mMã®ç¯å²ã§ããããå¯æº¶åã¯å žåçã«ã¯
20âã25âã®ç¯å²ã®æž©åºŠã«ãããŠãåºçžãšå¯æº¶å
åªäœãšã®éã®æ¥è§Šãä¿é²ããããã«æ··åããªãã
è¡ããäžå±€é«ã枩床ã¯äžææã®E.ã³ãªèçœè³ªãå¯
溶åããã§ãããããµã³ãã«ã15åé眮ããåã¯
溶液ãåéæã«ãªã€ãæã«å¯æº¶åãå®äºãããšè
ãããããå¯æº¶åã®å®äºåŸäžèŠç©ãåé¢ããã
ILâïŒãå¯æº¶åãããåŸãå Žåã«ãã€ãŠã¯LI
âïŒãæ°Žæ§æº¶æ¶²ããéå æ¡ä»¶äžã§ïŒâãã¿ããŒã«
åã¯ïŒâã¡ãã«âïŒâãã¿ããŒã«ã«ããæœåºã
ãŠãILâïŒãšéåžžã«è¿ãååéãæãã幟ãã
ã®æ±æç©ãèããå«æããè¿œå ã®E.ã³ãªèçœè³ªã
é€å»ãããæ°Žæ§æº¶æ¶²åã³ãã¿ããŒã«ãå®è³ªäžäžæ··
åæ§ã§ããæ¡ä»¶ïŒäŸãã°ã0.05ã0.15ã®ç¯å²ã®ã€
ãªã³åŒ·åºŠïŒãçšãããææ©æœåºã®å®æœã«ãããŠã
å¿ èŠã§ããã°ãæ°Žæ§æº¶æ¶²ã®èçœè³ªæ¿åºŠã奜ãŸãã
ã¯çŽïŒmgïŒmlæªæºã奜ãŸããã¯çŽ0.5ãïŒmgïŒml
ã«èª¿æŽãããéå å€ïŒäŸãã°DTTïŒã®ååšäžã§
æœåºãè¡ãããšã«ãã€ãŠéå æ¡ä»¶ãç¶æãããã
ã¿ããŒã«ã¯äžè¬ã«å¯æº¶åãããILâïŒã®æ°Žæ§æº¶
液ã«çŽïŒïŒïŒãçŽïŒïŒïŒïŒæœåºå€ïŒæ°Žæº¶æ¶²ïŒã®ç¯
å²ã®ã奜ãŸããã¯çŽïŒïŒïŒã®å®¹éæ¯ã«ãããŠæ·»å
ãããã§ãããã枩床ã¯äžè¬ã«20âã100âã®ç¯
å²ã§ããããããŠPHã¯äžè¬ã«çŽïŒãïŒã奜ãŸãã
ã¯çŽïŒãïŒã§ãããã溶液ãšãã¿ããŒã«ãšã®éã®
æ¥è§Šæéã¯èšççã§ã¯ãªãããããŠæ°åéã®ãªãŒ
ããŒã®æ¯èŒççãæéãçšããããšãã§ãããæœ
åºãå®äºããåŸãæ°Žçžåã³ãã¿ããŒã«çžãåé¢
ãããããŠãã¿ããŒã«çžããILâïŒãåé¢ããã
ãã¿ããŒã«çžããILâïŒãåé¢ããããã®å¥œãŸ
ããæ¹æ³ã¯é žæ²æŸ±ã§ãããããã¯ãææ©çžã溶解
ãããŸã§ïŒææ©çžã®å®¹éã«å¯ŸããŠçŽïŒãïŒå®¹éã®
ç·©è¡æ¶²ïŒãã¿ããŒã«çžãæ°Žæ§ç·©è¡æ¶²ïŒPH7.5ïŒã«
å ãããããŠæ¬¡ã«PHãçŽ5.5ã7.0ã奜ãŸããã¯6.0
ã6.2ã«äœäžããããŠILâïŒãæ²æŸ±ããããããš
ã«ããè¡ãããã
âïŒãæ°Žæ§æº¶æ¶²ããéå æ¡ä»¶äžã§ïŒâãã¿ããŒã«
åã¯ïŒâã¡ãã«âïŒâãã¿ããŒã«ã«ããæœåºã
ãŠãILâïŒãšéåžžã«è¿ãååéãæãã幟ãã
ã®æ±æç©ãèããå«æããè¿œå ã®E.ã³ãªèçœè³ªã
é€å»ãããæ°Žæ§æº¶æ¶²åã³ãã¿ããŒã«ãå®è³ªäžäžæ··
åæ§ã§ããæ¡ä»¶ïŒäŸãã°ã0.05ã0.15ã®ç¯å²ã®ã€
ãªã³åŒ·åºŠïŒãçšãããææ©æœåºã®å®æœã«ãããŠã
å¿ èŠã§ããã°ãæ°Žæ§æº¶æ¶²ã®èçœè³ªæ¿åºŠã奜ãŸãã
ã¯çŽïŒmgïŒmlæªæºã奜ãŸããã¯çŽ0.5ãïŒmgïŒml
ã«èª¿æŽãããéå å€ïŒäŸãã°DTTïŒã®ååšäžã§
æœåºãè¡ãããšã«ãã€ãŠéå æ¡ä»¶ãç¶æãããã
ã¿ããŒã«ã¯äžè¬ã«å¯æº¶åãããILâïŒã®æ°Žæ§æº¶
液ã«çŽïŒïŒïŒãçŽïŒïŒïŒïŒæœåºå€ïŒæ°Žæº¶æ¶²ïŒã®ç¯
å²ã®ã奜ãŸããã¯çŽïŒïŒïŒã®å®¹éæ¯ã«ãããŠæ·»å
ãããã§ãããã枩床ã¯äžè¬ã«20âã100âã®ç¯
å²ã§ããããããŠPHã¯äžè¬ã«çŽïŒãïŒã奜ãŸãã
ã¯çŽïŒãïŒã§ãããã溶液ãšãã¿ããŒã«ãšã®éã®
æ¥è§Šæéã¯èšççã§ã¯ãªãããããŠæ°åéã®ãªãŒ
ããŒã®æ¯èŒççãæéãçšããããšãã§ãããæœ
åºãå®äºããåŸãæ°Žçžåã³ãã¿ããŒã«çžãåé¢
ãããããŠãã¿ããŒã«çžããILâïŒãåé¢ããã
ãã¿ããŒã«çžããILâïŒãåé¢ããããã®å¥œãŸ
ããæ¹æ³ã¯é žæ²æŸ±ã§ãããããã¯ãææ©çžã溶解
ãããŸã§ïŒææ©çžã®å®¹éã«å¯ŸããŠçŽïŒãïŒå®¹éã®
ç·©è¡æ¶²ïŒãã¿ããŒã«çžãæ°Žæ§ç·©è¡æ¶²ïŒPH7.5ïŒã«
å ãããããŠæ¬¡ã«PHãçŽ5.5ã7.0ã奜ãŸããã¯6.0
ã6.2ã«äœäžããããŠILâïŒãæ²æŸ±ããããããš
ã«ããè¡ãããã
ãã®æ¹æ³ã®æ¬¡ã®æ®µéã¯ãçµæILâïŒãæœåºã®
åŸã«æ®çããE.ã³ãªæ±æç©ããåé¢ãããããŠæ
é©ã«ã¯å¯æº¶åå€ãããåé¢ããããšã§ãããã²ã«
æ¿Ÿéã¯ãããã°ã©ãã€ãŒãRPâHPLCãåã¯ã²
ã«æ¿Ÿéã¯ãããã°ã©ãã€ãŒãšRPâHPLCãšã®çµ
åããã䜿çšããããã²ã«æ¿Ÿéã¯ãããã°ã©ãã€
ãŒã¯å¥œãŸããã¯ãçºç±æåãåã³çµæILâïŒã
ãé«ããåã¯äœãååéãæããèçœè³ªæ±æç©ã
é€å»ããïŒæ®µéã«ãããŠè¡ããããïŒçµæILâïŒ
ã¯çŽ15.5Kãã«ãã³ã®ååéãæãããïŒããã
ã®æ±æç©ããã®ILâïŒåé¢ãå¯èœã«ããããã«
溶液ãç»åããããšãã§ããã²ã«ã¯åæ¥çã«å ¥æ
å¯èœã§ãããã»ãã¢ã¯ãªã«ïŒ³â200ã¯é«ãååé
ã®æåãé€å»ããããã«å¥œãŸããã²ã«ã§ãããã
ããŠã»ãã¢ããã¯ã¹ïŒ§â25ãâ75åã¯ïŒ§â100
ã²ã«ã¯äœååéæ±æç©ãé€å»ããããã«å¥œãŸã
ããã²ã«æ¿Ÿéãªå žåçã«ã¯ãçŽ0.1ã10ïŒ ã®å¯æº¶
åå€åã³çŽïŒã10mMéå å€ãå«æããç·©è¡å溶
液ïŒPH5.5ã7.0ïŒäžã§è¡ããããã«ã©ã ã¯ãææ
ã®æåãé©åã«åããããšãã§ãããããªå€§ãã
ã«ãããã§ãããã
åŸã«æ®çããE.ã³ãªæ±æç©ããåé¢ãããããŠæ
é©ã«ã¯å¯æº¶åå€ãããåé¢ããããšã§ãããã²ã«
æ¿Ÿéã¯ãããã°ã©ãã€ãŒãRPâHPLCãåã¯ã²
ã«æ¿Ÿéã¯ãããã°ã©ãã€ãŒãšRPâHPLCãšã®çµ
åããã䜿çšããããã²ã«æ¿Ÿéã¯ãããã°ã©ãã€
ãŒã¯å¥œãŸããã¯ãçºç±æåãåã³çµæILâïŒã
ãé«ããåã¯äœãååéãæããèçœè³ªæ±æç©ã
é€å»ããïŒæ®µéã«ãããŠè¡ããããïŒçµæILâïŒ
ã¯çŽ15.5Kãã«ãã³ã®ååéãæãããïŒããã
ã®æ±æç©ããã®ILâïŒåé¢ãå¯èœã«ããããã«
溶液ãç»åããããšãã§ããã²ã«ã¯åæ¥çã«å ¥æ
å¯èœã§ãããã»ãã¢ã¯ãªã«ïŒ³â200ã¯é«ãååé
ã®æåãé€å»ããããã«å¥œãŸããã²ã«ã§ãããã
ããŠã»ãã¢ããã¯ã¹ïŒ§â25ãâ75åã¯ïŒ§â100
ã²ã«ã¯äœååéæ±æç©ãé€å»ããããã«å¥œãŸã
ããã²ã«æ¿Ÿéãªå žåçã«ã¯ãçŽ0.1ã10ïŒ ã®å¯æº¶
åå€åã³çŽïŒã10mMéå å€ãå«æããç·©è¡å溶
液ïŒPH5.5ã7.0ïŒäžã§è¡ããããã«ã©ã ã¯ãææ
ã®æåãé©åã«åããããšãã§ãããããªå€§ãã
ã«ãããã§ãããã
RPâHPLCã¯ã²ã«æ¿Ÿéã«ä»£ããã®ã§ãããã
ãã«ãRPâHPLCã¯ãçµæILâïŒã«è¿ãååé
ãæããããŠããæ ã«ã²ã«æ¿Ÿéã«ãã€ãŠã¯å®å šã«
é€å»ããåŸãªãååãé€å»ããããšãã§ãããã
ãã«ãRPâHPLCã«ãã€ãŠçŽ°èãšã³ãããã·ã³
ã®ããšãæ±æç©ãå¹æçã«é€å»ããããåŸã€ãŠã
RPâHPLCã¯ã²ã«æ¿ŸéåŸã®æçµç²Ÿè£œæ®µéãšããŠ
ã䜿çšããåŸããèçœè³ªã®è¯å¥œãªåé¢ããããã
æ¯æäœïŒåºå®çžïŒããŸãã²ã«æ¿ŸéåŸã®æçµç²Ÿè£œæ®µ
éãšããŠäœ¿çšããåŸããèçœè³ªã®è¯å¥œãªåé¢ãã
ãããæ¯æäœïŒåºå®çžïŒãRPâHPLCã«ãããŠ
䜿çšããããšãã§ãããâïŒãâïŒåã¯ïŒ£â
18ã®300ãªã³ã°ã¹ãããŒã ååŸæ¯æäœã奜ãŸãã
æ¯æäœã®äŸã§ãããILâïŒã溶液ç¶ã«ç¶æãã
ãããåé¢ã¯çŽ2.5以äžãéåžžã¯2.1ã2.3ã®é žæ§PH
ã«ãããŠè¡ããããããã«é¢ããå¯æº¶åïŒã²ã«æ¿Ÿ
éïŒããã®æº¶æ¶²ã®PHã¯å¥œãŸããã¯ãã®ç¯å²ã«èª¿æŽ
ãããã§ãããã溶液ãRPâHPLCã«ã©ã ã«è²
è·ãããããŠåºå®çžã«åžçãããããé ¢é žåã¯ã
ãªãã«ãªãé ¢é žã®ããšãææ©é žãšãããããŒã«å
ã¯ã¢ã»ããããªã«ã®ããšãææ©æº¶å€ãšãå«ãã§æ
ãã°ã©ãžãšã³ã溶å€åœ¢ãçšããŠã«ã©ã ããçµæ
ILâïŒã溶åºãããé ¢é žâãããããŒã«ãããª
ãã«ãªãé ¢é žâãããããŒã«ãåã³ããªãã«ãªã
é ¢é žâã¢ã»ããããªã«ã奜ãŸãã溶å€ç³»ã§ããã
çµæILâïŒã¯é ¢é žâãããããŒã«ç³»ã«ãããŠçŽ
40ïŒ ãããããŒã«ã§ãããªãã«ãªãé ¢é žâããã
ããŒã«ç³»ã«ãããŠçŽ50ïŒ ãããããŒã«ã§ããããŠ
ããªãã«ãªãé ¢é žâã¢ã»ããããªã«ç³»ã«ãããŠçŽ
62ïŒ ã¢ã»ããããªã«ã§æº¶åºããã䟿å®äžã溶é¢æ¶²
ã®ææ©æº¶å€å«éã¯ãçµæäœILâïŒã溶åºãã溶
å€æ¿åºŠãã幟åäœãã¬ãã«ãŸã§æ¥éã«äžæãã
ãã次ã«çŽ0.1ïŒã1.0ïŒ ïŒåã®ç¯å²ã®ãããããª
ã°ã©ãžãšã³ãå€åã«ãã溶åºããã
ãã«ãRPâHPLCã¯ãçµæILâïŒã«è¿ãååé
ãæããããŠããæ ã«ã²ã«æ¿Ÿéã«ãã€ãŠã¯å®å šã«
é€å»ããåŸãªãååãé€å»ããããšãã§ãããã
ãã«ãRPâHPLCã«ãã€ãŠçŽ°èãšã³ãããã·ã³
ã®ããšãæ±æç©ãå¹æçã«é€å»ããããåŸã€ãŠã
RPâHPLCã¯ã²ã«æ¿ŸéåŸã®æçµç²Ÿè£œæ®µéãšããŠ
ã䜿çšããåŸããèçœè³ªã®è¯å¥œãªåé¢ããããã
æ¯æäœïŒåºå®çžïŒããŸãã²ã«æ¿ŸéåŸã®æçµç²Ÿè£œæ®µ
éãšããŠäœ¿çšããåŸããèçœè³ªã®è¯å¥œãªåé¢ãã
ãããæ¯æäœïŒåºå®çžïŒãRPâHPLCã«ãããŠ
䜿çšããããšãã§ãããâïŒãâïŒåã¯ïŒ£â
18ã®300ãªã³ã°ã¹ãããŒã ååŸæ¯æäœã奜ãŸãã
æ¯æäœã®äŸã§ãããILâïŒã溶液ç¶ã«ç¶æãã
ãããåé¢ã¯çŽ2.5以äžãéåžžã¯2.1ã2.3ã®é žæ§PH
ã«ãããŠè¡ããããããã«é¢ããå¯æº¶åïŒã²ã«æ¿Ÿ
éïŒããã®æº¶æ¶²ã®PHã¯å¥œãŸããã¯ãã®ç¯å²ã«èª¿æŽ
ãããã§ãããã溶液ãRPâHPLCã«ã©ã ã«è²
è·ãããããŠåºå®çžã«åžçãããããé ¢é žåã¯ã
ãªãã«ãªãé ¢é žã®ããšãææ©é žãšãããããŒã«å
ã¯ã¢ã»ããããªã«ã®ããšãææ©æº¶å€ãšãå«ãã§æ
ãã°ã©ãžãšã³ã溶å€åœ¢ãçšããŠã«ã©ã ããçµæ
ILâïŒã溶åºãããé ¢é žâãããããŒã«ãããª
ãã«ãªãé ¢é žâãããããŒã«ãåã³ããªãã«ãªã
é ¢é žâã¢ã»ããããªã«ã奜ãŸãã溶å€ç³»ã§ããã
çµæILâïŒã¯é ¢é žâãããããŒã«ç³»ã«ãããŠçŽ
40ïŒ ãããããŒã«ã§ãããªãã«ãªãé ¢é žâããã
ããŒã«ç³»ã«ãããŠçŽ50ïŒ ãããããŒã«ã§ããããŠ
ããªãã«ãªãé ¢é žâã¢ã»ããããªã«ç³»ã«ãããŠçŽ
62ïŒ ã¢ã»ããããªã«ã§æº¶åºããã䟿å®äžã溶é¢æ¶²
ã®ææ©æº¶å€å«éã¯ãçµæäœILâïŒã溶åºãã溶
å€æ¿åºŠãã幟åäœãã¬ãã«ãŸã§æ¥éã«äžæãã
ãã次ã«çŽ0.1ïŒã1.0ïŒ ïŒåã®ç¯å²ã®ãããããª
ã°ã©ãžãšã³ãå€åã«ãã溶åºããã
çµæILâïŒãã¯ãããã°ã©ãã€ãŒæ®µéããå
åããããšããããããåçµä¹ŸãããããŠéå å€
ïŒçµæILâïŒãéå ç¶æ ã«ä¿ã€ããïŒåã³å¯æº¶å
å€ïŒããã溶液ç¶ã«ä¿ã€ããïŒãå«æããäžæ§æ°Ž
æ§ç·©è¡æ¶²äžã«åæžæ¿ãããããçµæäœILâïŒã¯
ãã®åœ¢ã§å®å®ã§ããããããŠããã«åŠçããã
ããåã³äœ¿çšåã«è£œå€åããããã«è²¯èµããããš
ãã§ããã
åããããšããããããåçµä¹ŸãããããŠéå å€
ïŒçµæILâïŒãéå ç¶æ ã«ä¿ã€ããïŒåã³å¯æº¶å
å€ïŒããã溶液ç¶ã«ä¿ã€ããïŒãå«æããäžæ§æ°Ž
æ§ç·©è¡æ¶²äžã«åæžæ¿ãããããçµæäœILâïŒã¯
ãã®åœ¢ã§å®å®ã§ããããããŠããã«åŠçããã
ããåã³äœ¿çšåã«è£œå€åããããã«è²¯èµããããš
ãã§ããã
ãã®ä»ã®ãããŠå¥œãŸããæ¹æ³ã¯ãçµæILâïŒ
ãããããã²ã«æ¿Ÿéã«ããåé¢ãããåŸã«å¶åŸ¡ã
ããæ¡ä»¶äžã§éžæçã«é žåãããããŠé žåããã
çæç©ãRPâHPCLã«ããåã¯RPâHPLCã«ç¶
ãã²ã«æ¿Ÿéã«ãã粟補ããããšã§ãããããã¯ã
ã²ã«æ¿Ÿéã«ããããããååšãç¶ããæ±æç©ãå
ã³äžææã®é žåçæç©ã®å¹æçãªé€å»ãããã
ãã奜ãŸããé žåæ¹æ³ã¯ãçµæILâïŒèçœè³ªãš
å®è³ªäžã®ã¢ããé žé åãæããååã«éå ããã
埮çç©çã«çç£ãããåæçµæILâïŒèçœè³ª
ïŒè©²é åã¯ãæçšãªèçœè³ªäžã§ã¯58äœåã³105äœã«
ãããŠååå çµåããŠã·ã¹ãã³ãæ§æããã·ã¹ã
ã€ã³ãå«æããïŒããå¶åŸ¡ãããæ æ§ã«ãããŠéž
æçã«é žåããããšã«ãã€ãŠè©²ã·ã¹ãã€ã³ãéžæ
çã«é žåããŠ58äœåã³105äœã«ã·ã¹ãã³ã圢æã
ãããšã§ããããã«ã®ãŒç¹èš±No.898016äžã«èšèŒã
ããããŠã¯ã¬ãŒã ãããŠãããããªçµæILâïŒ
ã䜿çšãããå Žåãå¶åŸ¡ããããããŠéžæçãªé ž
åã®å¹çãæ¹è¯ãããããã®å Žåã125äœã®ã·ã¹
ãã€ã³ãé€å»ãããåã¯äžæ§ã¢ããé žã«ãã眮ã
æããããŠãããåŸã€ãŠILâïŒã®ãã€ããŒåã¯
ããªããŒã圢æããããšãã§ããé žåã®éã®125
äœã®ã·ã¹ãã€ã³ã«ããæ£ãããªãååå çµåå
ã³ïŒåã¯ååéçµåãåé¿ãããããã®æ¹æ³ã«ã
ããŠã¯ãååã«éå ããã埮çç©çã«çç£ããã
åæçµæILâïŒèçœè³ªã奜ãŸããã¯ïœâãšãŒã
ãœãã³ãŸãšãŒããåå¿ããããããã®é žåå€ã¯ã·
ã¹ãã€ã³ãæ°Žæ§åªäœäžã§ã該ã·ã¹ãã€ã³ã®pKaã
ãå°ãªããšãçŽ0.5PHãŠãããäœãPHã«ãããŠé ž
åãããã®å Žåãåå¿æ··åç©äžã®åæèçœè³ªã®æ¿
床ã¯çŽïŒmgïŒmlããäœãããããŠïœâãšãŒããœã³
ãã³ãŸãšãŒããšèçœè³ªãšã®ã¢ã«æ¯ã¯å°ãªããšãå
åŠéè«çã§ãããäœããïœâãšãŒããœã³ãã³ãŸãš
ãŒãã¯åå¿ã®æ«æã«ãããŠéå°ã«ååšããããã®
éžæçé žåã¯çç©åŠçã«æŽ»æ§ãªååãçæããã
ããéžæçã«é žåãããçæç©ã®RPâHPLC粟
補ã¯äžèšã®æ¡ä»¶äžã§ãéå å€ã®äžååšäžãåã³äž
èšã®ã²ã«æ¿Ÿéã«ãããŠäœ¿çšããã®ãšåãæ¿åºŠåã¯
ããããäœãæ¿åºŠã§ã®æŽå€ã®ååšäžã§è¡ãããã
ãããããã²ã«æ¿Ÿéã«ããåé¢ãããåŸã«å¶åŸ¡ã
ããæ¡ä»¶äžã§éžæçã«é žåãããããŠé žåããã
çæç©ãRPâHPCLã«ããåã¯RPâHPLCã«ç¶
ãã²ã«æ¿Ÿéã«ãã粟補ããããšã§ãããããã¯ã
ã²ã«æ¿Ÿéã«ããããããååšãç¶ããæ±æç©ãå
ã³äžææã®é žåçæç©ã®å¹æçãªé€å»ãããã
ãã奜ãŸããé žåæ¹æ³ã¯ãçµæILâïŒèçœè³ªãš
å®è³ªäžã®ã¢ããé žé åãæããååã«éå ããã
埮çç©çã«çç£ãããåæçµæILâïŒèçœè³ª
ïŒè©²é åã¯ãæçšãªèçœè³ªäžã§ã¯58äœåã³105äœã«
ãããŠååå çµåããŠã·ã¹ãã³ãæ§æããã·ã¹ã
ã€ã³ãå«æããïŒããå¶åŸ¡ãããæ æ§ã«ãããŠéž
æçã«é žåããããšã«ãã€ãŠè©²ã·ã¹ãã€ã³ãéžæ
çã«é žåããŠ58äœåã³105äœã«ã·ã¹ãã³ã圢æã
ãããšã§ããããã«ã®ãŒç¹èš±No.898016äžã«èšèŒã
ããããŠã¯ã¬ãŒã ãããŠãããããªçµæILâïŒ
ã䜿çšãããå Žåãå¶åŸ¡ããããããŠéžæçãªé ž
åã®å¹çãæ¹è¯ãããããã®å Žåã125äœã®ã·ã¹
ãã€ã³ãé€å»ãããåã¯äžæ§ã¢ããé žã«ãã眮ã
æããããŠãããåŸã€ãŠILâïŒã®ãã€ããŒåã¯
ããªããŒã圢æããããšãã§ããé žåã®éã®125
äœã®ã·ã¹ãã€ã³ã«ããæ£ãããªãååå çµåå
ã³ïŒåã¯ååéçµåãåé¿ãããããã®æ¹æ³ã«ã
ããŠã¯ãååã«éå ããã埮çç©çã«çç£ããã
åæçµæILâïŒèçœè³ªã奜ãŸããã¯ïœâãšãŒã
ãœãã³ãŸãšãŒããåå¿ããããããã®é žåå€ã¯ã·
ã¹ãã€ã³ãæ°Žæ§åªäœäžã§ã該ã·ã¹ãã€ã³ã®pKaã
ãå°ãªããšãçŽ0.5PHãŠãããäœãPHã«ãããŠé ž
åãããã®å Žåãåå¿æ··åç©äžã®åæèçœè³ªã®æ¿
床ã¯çŽïŒmgïŒmlããäœãããããŠïœâãšãŒããœã³
ãã³ãŸãšãŒããšèçœè³ªãšã®ã¢ã«æ¯ã¯å°ãªããšãå
åŠéè«çã§ãããäœããïœâãšãŒããœã³ãã³ãŸãš
ãŒãã¯åå¿ã®æ«æã«ãããŠéå°ã«ååšããããã®
éžæçé žåã¯çç©åŠçã«æŽ»æ§ãªååãçæããã
ããéžæçã«é žåãããçæç©ã®RPâHPLC粟
補ã¯äžèšã®æ¡ä»¶äžã§ãéå å€ã®äžååšäžãåã³äž
èšã®ã²ã«æ¿Ÿéã«ãããŠäœ¿çšããã®ãšåãæ¿åºŠåã¯
ããããäœãæ¿åºŠã§ã®æŽå€ã®ååšäžã§è¡ãããã
ã¯ãããã°ã©ã段éåŸã®çµæILâïŒã®çŽåºŠã¯
95ïŒ ä»¥äžããããŠéåžžçŽ98ïŒ ä»¥äžã§ããããã®é«
床ã«çŽç²ãªç©è³ªã¯ã100000ãŠãããã®ILâïŒæŽ»
æ§å€åœãçŽ5nïœæªæºã®ãšã³ãããã·ã³ãéåžžçŽ
0.01nïœæªæºã®ãšã³ãããã·ã³ãå«æããã
95ïŒ ä»¥äžããããŠéåžžçŽ98ïŒ ä»¥äžã§ããããã®é«
床ã«çŽç²ãªç©è³ªã¯ã100000ãŠãããã®ILâïŒæŽ»
æ§å€åœãçŽ5nïœæªæºã®ãšã³ãããã·ã³ãéåžžçŽ
0.01nïœæªæºã®ãšã³ãããã·ã³ãå«æããã
ãã®çºæã«åŸãçµæILâïŒã®è£œå€åã¯ã粟補
ããéžæçã«é žåãããILâïŒãçšããå¥åã®
æäœãšããŠãåã¯éžæçã«é žåãããILâïŒã®
粟補ãšäžäœåãããæäœã«ãããŠè¡ãããšãã§ã
ããåŸè ã®å Žåã補å€åã®ããã®åºçºææã¯ãéž
æçã«é žåãããçæç©ã®éçžé«é液äœã¯ããã
ã°ã©ãã€ãŒïŒRPâHPLCïŒåŠçããã®çµæILâ
ïŒå«æçæç©ã§ããã奜ãŸããã¯éžæçã«é žåã
ããçµæILâïŒãå«ãRPâHPLCçæç©ïŒããŒ
ã«ç©ãšã称ããïŒã¯æ°Žâææ©æº¶å€æ··åç©äžçµæ
ILâïŒã®æº¶æ¶²ãå«ãã§æãã§ããããææ©æº¶å€
ã®çš®é¡ã¯RPâHPLCã«ãããŠäœ¿çšããã溶å€ç³»
ã«äŸåããã§ãããã䜿çšããåŸãç³»ã®åã¯é ¢é ž
åã¯ããªãã«ãªãé ¢é žã®ããšãææ©é žãšãããã
ãŒã«åã¯ã¢ã»ããããªã«ã®ããšãææ©æº¶å€ãšã®çµ
åããã§ããã
ããéžæçã«é žåãããILâïŒãçšããå¥åã®
æäœãšããŠãåã¯éžæçã«é žåãããILâïŒã®
粟補ãšäžäœåãããæäœã«ãããŠè¡ãããšãã§ã
ããåŸè ã®å Žåã補å€åã®ããã®åºçºææã¯ãéž
æçã«é žåãããçæç©ã®éçžé«é液äœã¯ããã
ã°ã©ãã€ãŒïŒRPâHPLCïŒåŠçããã®çµæILâ
ïŒå«æçæç©ã§ããã奜ãŸããã¯éžæçã«é žåã
ããçµæILâïŒãå«ãRPâHPLCçæç©ïŒããŒ
ã«ç©ãšã称ããïŒã¯æ°Žâææ©æº¶å€æ··åç©äžçµæ
ILâïŒã®æº¶æ¶²ãå«ãã§æãã§ããããææ©æº¶å€
ã®çš®é¡ã¯RPâHPLCã«ãããŠäœ¿çšããã溶å€ç³»
ã«äŸåããã§ãããã䜿çšããåŸãç³»ã®åã¯é ¢é ž
åã¯ããªãã«ãªãé ¢é žã®ããšãææ©é žãšãããã
ãŒã«åã¯ã¢ã»ããããªã«ã®ããšãææ©æº¶å€ãšã®çµ
åããã§ããã
ãã®ãããªRPâHPLCããŒã«ç©ããçµæäœIL
âïŒã補å€åãã第ïŒæ®µéã¯ãçµæILâïŒã®æ°Ž
äžãžã®æº¶è§£æ§ãå¢åŒ·ããSDSåã¯ãµã«ã³ã·ã«ã®ã
ãšãæŽå€ãå«æããæ°Žæ§ç·©è¡æ¶²äžã«ããŒã«ç©ãå
æžæ¿ïŒåžéïŒããããšã«ããæ··åç©ãæ°Žæ§ããã
ãšã§ããããã®åžéã®åŸãææ©çžãçµæäœILâ
ïŒå«ææ°Žæ§çžããé€å»ãããããŠé©åœãªç·©è¡æ¶²ã
çšããéææ¿ŸéïŒdiaâfiltrationïŒã«ããæŽå€æ¿
床ãäœäžãããããSDSã䜿çšããå ŽåãSDSã
çŽ100ã250ã奜ãŸããã¯çŽ200ÎŒïœïŒmgILâïŒã®
ã¬ãã«ã«äœäžãããããéææ¿Ÿéã®åŸãILâïŒ
æ¿åºŠãçŽ0.01ãïŒmgïŒmlã®ç¯å²ã®æ¿åºŠã«èª¿æŽãã
ãããŠæ°Žæº¶æ§æ äœãææã®ã¬ãã«ã«å ããããã®
æ äœã¯å žåçã«ã¯ãããã溶液äžã«çŽïŒã10éé
ïŒ ã奜ãŸããã¯çŽïŒééïŒ ã§ååšããããã«æ·»å
ãããã§ããããæ·»å ãããæ äœã®æ£ç¢ºãªéã¯èš
ççã§ã¯ãªããå»è¬é å€ã®è£œé ã«ãããŠäœ¿çšãã
ãåžžçšã®åºäœå¢éå€ãæ äœãšããŠäœ¿çšããããšã
ã§ããããããã®ææã¯æ°Žæº¶æ§ã§ãããILâïŒ
ãšåå¿ããããããŠããèªäœå®å®ã§ãããããã
ã¯å¥œãŸããã¯æ°Žã«å¯ŸããŠéâæåæ§ïŒããªãã¡ã
éåžæ¹¿æ§ïŒã§ãããæ·»å ããåŸãæ äœã®äŸã¯ã©ã¯
ããŒã¹ããã³ãããŒã«ãåã³ä»ã®éå ç³äŸãã°ãœ
ã«ãããŒã«ãå°éºŠãããŠã¢ãã³ã·ãç±³ãåã³ãã€
ã¬ã·ãšã«ç±æ¥ãã柱ç²åã³æŸ±ç²å æ°Žå解ç©ããã¯
ãã¯ãªã¹ã¿ãªã³ã»ã«ããŒã¹ã䞊ã³ã«ã¢ã«ããã³ã
äŸãã°ããè¡æž ã¢ã«ããã³ã§ããããã³ãããŒã«
ã奜ãŸããã
âïŒã補å€åãã第ïŒæ®µéã¯ãçµæILâïŒã®æ°Ž
äžãžã®æº¶è§£æ§ãå¢åŒ·ããSDSåã¯ãµã«ã³ã·ã«ã®ã
ãšãæŽå€ãå«æããæ°Žæ§ç·©è¡æ¶²äžã«ããŒã«ç©ãå
æžæ¿ïŒåžéïŒããããšã«ããæ··åç©ãæ°Žæ§ããã
ãšã§ããããã®åžéã®åŸãææ©çžãçµæäœILâ
ïŒå«ææ°Žæ§çžããé€å»ãããããŠé©åœãªç·©è¡æ¶²ã
çšããéææ¿ŸéïŒdiaâfiltrationïŒã«ããæŽå€æ¿
床ãäœäžãããããSDSã䜿çšããå ŽåãSDSã
çŽ100ã250ã奜ãŸããã¯çŽ200ÎŒïœïŒmgILâïŒã®
ã¬ãã«ã«äœäžãããããéææ¿Ÿéã®åŸãILâïŒ
æ¿åºŠãçŽ0.01ãïŒmgïŒmlã®ç¯å²ã®æ¿åºŠã«èª¿æŽãã
ãããŠæ°Žæº¶æ§æ äœãææã®ã¬ãã«ã«å ããããã®
æ äœã¯å žåçã«ã¯ãããã溶液äžã«çŽïŒã10éé
ïŒ ã奜ãŸããã¯çŽïŒééïŒ ã§ååšããããã«æ·»å
ãããã§ããããæ·»å ãããæ äœã®æ£ç¢ºãªéã¯èš
ççã§ã¯ãªããå»è¬é å€ã®è£œé ã«ãããŠäœ¿çšãã
ãåžžçšã®åºäœå¢éå€ãæ äœãšããŠäœ¿çšããããšã
ã§ããããããã®ææã¯æ°Žæº¶æ§ã§ãããILâïŒ
ãšåå¿ããããããŠããèªäœå®å®ã§ãããããã
ã¯å¥œãŸããã¯æ°Žã«å¯ŸããŠéâæåæ§ïŒããªãã¡ã
éåžæ¹¿æ§ïŒã§ãããæ·»å ããåŸãæ äœã®äŸã¯ã©ã¯
ããŒã¹ããã³ãããŒã«ãåã³ä»ã®éå ç³äŸãã°ãœ
ã«ãããŒã«ãå°éºŠãããŠã¢ãã³ã·ãç±³ãåã³ãã€
ã¬ã·ãšã«ç±æ¥ãã柱ç²åã³æŸ±ç²å æ°Žå解ç©ããã¯
ãã¯ãªã¹ã¿ãªã³ã»ã«ããŒã¹ã䞊ã³ã«ã¢ã«ããã³ã
äŸãã°ããè¡æž ã¢ã«ããã³ã§ããããã³ãããŒã«
ã奜ãŸããã
æ
äœã¯è£œå€ã«åµ©ãå ããåäœæäžéã®æº¶æ¶²ã容
åšãäŸãã°ç¡èãã€ã¢ã«äžã§åçµä¹Ÿç¥ãããå Žå
ã«åçµä¹Ÿç¥ãããæ®æž£ãèçŒã«ããæçã«èå¥ã§
ããããã«ãããããã«é¢ãã奜ãŸããæ äœã§ã
ããã³ãããŒã«ã¯ãæ°Žã«æåæ§ã§ãªãçŸçã«èš±å®¹
ãããïŒçœè²ãçµæ¶æ§ïŒæ®æž£ããããããæ°Žã«å¯Ÿ
ãããã³ãããŒã«ã®éæåæ§ã¯è£œå€ã®å®å®æ§ãå¢
匷ããã§ãããã
åšãäŸãã°ç¡èãã€ã¢ã«äžã§åçµä¹Ÿç¥ãããå Žå
ã«åçµä¹Ÿç¥ãããæ®æž£ãèçŒã«ããæçã«èå¥ã§
ããããã«ãããããã«é¢ãã奜ãŸããæ äœã§ã
ããã³ãããŒã«ã¯ãæ°Žã«æåæ§ã§ãªãçŸçã«èš±å®¹
ãããïŒçœè²ãçµæ¶æ§ïŒæ®æž£ããããããæ°Žã«å¯Ÿ
ãããã³ãããŒã«ã®éæåæ§ã¯è£œå€ã®å®å®æ§ãå¢
匷ããã§ãããã
æ
äœãæ·»å ããåŸãåäœæäžéïŒããªãã¡ãæ
äžåœã0.01ãïŒmgã奜ãŸããã¯0.2ã0.3mgã®ILâ
ïŒããããã容éïŒã®æº¶æ¶²ã容åšã«åé ããæ€ã®
容åšã«ã¹ãããæ ããã¶ãããããŠåžžçšãªåçµä¹Ÿ
ç¥æ¡ä»¶åã³çšããŠåçµä¹Ÿç¥ããã
äžåœã0.01ãïŒmgã奜ãŸããã¯0.2ã0.3mgã®ILâ
ïŒããããã容éïŒã®æº¶æ¶²ã容åšã«åé ããæ€ã®
容åšã«ã¹ãããæ ããã¶ãããããŠåžžçšãªåçµä¹Ÿ
ç¥æ¡ä»¶åã³çšããŠåçµä¹Ÿç¥ããã
åçµä¹Ÿç¥ãããç¡èæ§æåç©ã¯(1)çµæILâïŒã
(2)æ äœïŒãã³ãããŒã«ïŒã(3)æŽå€ïŒSDSïŒãåã³(4)
æ··åç©ãåæ§æïŒreconstituteïŒãããå Žåã«ç
ççPHãããããå°éã®ç·©è¡å€ã®æ··åç©ããæ
ããçµæILâïŒã¯å žåçã«ã¯æ··åç©ã®çŽ0.015é
éïŒ ã3.85ééïŒ ãå ããããã«å¥œãŸããã¯æ··å
ç©ã®çŽ0.4ïŒ ã0.6ïŒ ãå ããã§ãããããã®çæ
ç©ã®è²¯èµè©Šéšã¯ãILâïŒããã®åœ¢æ äžã§ïŒâã
ïŒâã«ãããŠïŒç®æããé·æéå®å®ã§ããããšã
瀺ãã
(2)æ äœïŒãã³ãããŒã«ïŒã(3)æŽå€ïŒSDSïŒãåã³(4)
æ··åç©ãåæ§æïŒreconstituteïŒãããå Žåã«ç
ççPHãããããå°éã®ç·©è¡å€ã®æ··åç©ããæ
ããçµæILâïŒã¯å žåçã«ã¯æ··åç©ã®çŽ0.015é
éïŒ ã3.85ééïŒ ãå ããããã«å¥œãŸããã¯æ··å
ç©ã®çŽ0.4ïŒ ã0.6ïŒ ãå ããã§ãããããã®çæ
ç©ã®è²¯èµè©Šéšã¯ãILâïŒããã®åœ¢æ äžã§ïŒâã
ïŒâã«ãããŠïŒç®æããé·æéå®å®ã§ããããšã
瀺ãã
åçµä¹Ÿç¥ãããæ··åç©ã¯ãåžžçšã®éçµè
žçæ°Žæ§
泚å°å€ãäŸãã°æ³šå°çšæ°Žããªã³ã²ã«æ³šå°å€ãã°ã«
ã³ãŒã¹æ³šå°å€ãã°ã«ã³ãŒã¹åã³å¡©æ³šå°å€çããã€
ã¢ã«ã«æ³šå ¥ããããšã«ãã€ãŠåæ§æããããšãã§
ãããéå°ã®çºæ³¡ãé²æ¢ãããã泚å°å€ã¯ãã€ã¢
ã«ã®åŽå£ã«å¯ŸããŠäžãããããã¹ãã§ããããã€
ã¢ã«ã«æ·»å ããã泚å°å€ã®éã¯å žåçã«ã¯ïŒãïŒ
mlã奜ãŸããã¯ïŒãïŒmlã®ç¯å²ã§ããã
泚å°å€ãäŸãã°æ³šå°çšæ°Žããªã³ã²ã«æ³šå°å€ãã°ã«
ã³ãŒã¹æ³šå°å€ãã°ã«ã³ãŒã¹åã³å¡©æ³šå°å€çããã€
ã¢ã«ã«æ³šå ¥ããããšã«ãã€ãŠåæ§æããããšãã§
ãããéå°ã®çºæ³¡ãé²æ¢ãããã泚å°å€ã¯ãã€ã¢
ã«ã®åŽå£ã«å¯ŸããŠäžãããããã¹ãã§ããããã€
ã¢ã«ã«æ·»å ããã泚å°å€ã®éã¯å žåçã«ã¯ïŒãïŒ
mlã奜ãŸããã¯ïŒãïŒmlã®ç¯å²ã§ããã
åæ§æããã補å€ã¯ãããåã¯ä»ã®åºä¹³åç©ã«
察ããŠããããã«ILâïŒçæ³ãããããããã«
éçµè žæäžããã®ã«é©åœã§ããããã®ãããªçæ³
ã¯çš®ã ã®å ç«èª¿ç¯åŸ®åãäŸãã°ïŒŽçŽ°èå€ç°èªçºã
现èæ¯æ§ïŒŽçŽ°èã®èªå°ããããŠã©ã«ãã©ãŒçŽ°è掻
æ§ã®å¢å€§ãIFNâïœã®èªå°ã现èæ§å ç«ã®å埩å
ã¯å¢åŒ·ïŒäŸãã°ãå ç«äžå šç¶æ ã®æ²»çïŒãåã³çŽ°
èæ§ïŒcell mediafedïŒæè «ç掻æ§ã®å¢å€§ã®ãã
ã«é©åœã§ããã
察ããŠããããã«ILâïŒçæ³ãããããããã«
éçµè žæäžããã®ã«é©åœã§ããããã®ãããªçæ³
ã¯çš®ã ã®å ç«èª¿ç¯åŸ®åãäŸãã°ïŒŽçŽ°èå€ç°èªçºã
现èæ¯æ§ïŒŽçŽ°èã®èªå°ããããŠã©ã«ãã©ãŒçŽ°è掻
æ§ã®å¢å€§ãIFNâïœã®èªå°ã现èæ§å ç«ã®å埩å
ã¯å¢åŒ·ïŒäŸãã°ãå ç«äžå šç¶æ ã®æ²»çïŒãåã³çŽ°
èæ§ïŒcell mediafedïŒæè «ç掻æ§ã®å¢å€§ã®ãã
ã«é©åœã§ããã
次ã®äŸã¯ãã®çºæãããã«èª¬æããããã®äŸ
ã¯ããããªãæ æ§ã«ãããŠãçºæãéå®ããããš
ãæå³ããªãã
ã¯ããããªãæ æ§ã«ãããŠãçºæãéå®ããããš
ãæå³ããªãã
äŸ
ãã®äŸã«ãããŠäœ¿çšããçµæILâïŒã¯desâala
ILâ2ser125ã§ããããã®ILâïŒã®ã¢ããé žé å
ã¯ã倩ç¶ååã®æåã®ã¢ã©ãã³ãæ¬ ãããããŠ
125äœã®ã·ã¹ãã€ã³ã¬ã»ãªã³ã«å€ããããŠããç¹
ã«ãããŠå€©ç¶ããILâïŒã®ã¢ããé žé åãšç°ãã
ãã®ILâïŒãçç£ããE.ã³ãªã®ãµã³ãã«ã¯ãã·ã¿
ã¹ã»ã³ãŒãã¬ãŒã·ãšã³ã«ãããã¢ã¡ãªã«ã³ã»ã¿ã€
ãã»ã«ã«ããŠã¢ãŒã»ã³ã¬ã¯ã·ãšã³ã12301ããŒã¯
ã©ãŠã³ãã©ã€ããããã¯ãã«ãã¡ãªãŒã©ã³ããç±³
åœãã«1983幎ïŒæ26æ¥ã«åèšçªå·No.39452ãšããŠã
ãããŠãã¿ãã¹ãæ¡çŽã®èŠå®ã®ããšã«1984幎ïŒæ
ïŒæ¥ã«åèšçªå·No.39626ãšããŠå¯èšãããŠããã
ILâ2ser125ã§ããããã®ILâïŒã®ã¢ããé žé å
ã¯ã倩ç¶ååã®æåã®ã¢ã©ãã³ãæ¬ ãããããŠ
125äœã®ã·ã¹ãã€ã³ã¬ã»ãªã³ã«å€ããããŠããç¹
ã«ãããŠå€©ç¶ããILâïŒã®ã¢ããé žé åãšç°ãã
ãã®ILâïŒãçç£ããE.ã³ãªã®ãµã³ãã«ã¯ãã·ã¿
ã¹ã»ã³ãŒãã¬ãŒã·ãšã³ã«ãããã¢ã¡ãªã«ã³ã»ã¿ã€
ãã»ã«ã«ããŠã¢ãŒã»ã³ã¬ã¯ã·ãšã³ã12301ããŒã¯
ã©ãŠã³ãã©ã€ããããã¯ãã«ãã¡ãªãŒã©ã³ããç±³
åœãã«1983幎ïŒæ26æ¥ã«åèšçªå·No.39452ãšããŠã
ãããŠãã¿ãã¹ãæ¡çŽã®èŠå®ã®ããšã«1984幎ïŒæ
ïŒæ¥ã«åèšçªå·No.39626ãšããŠå¯èšãããŠããã
60ïŒ
ïŒâãããããŒã«ãïŒïŒ
é
¢é
žäž329mgã®RP
âHPLC粟補ãããé žåãããILâïŒçæç©ïŒè
çœè³ªæ¿åºŠ0.94mgïŒmlãã50mMé ¢é žãããªãŠã ã
1mMãšãã¬ã³ãžã¢ãã³åé ¢é žïŒEDTAïŒã0.1ïŒ
ããã·ã«ç¡«é žãããªãŠã ïŒSDSïŒïŒPH5.5ïŒäžã«10
åã«åžéããã
âHPLC粟補ãããé žåãããILâïŒçæç©ïŒè
çœè³ªæ¿åºŠ0.94mgïŒmlãã50mMé ¢é žãããªãŠã ã
1mMãšãã¬ã³ãžã¢ãã³åé ¢é žïŒEDTAïŒã0.1ïŒ
ããã·ã«ç¡«é žãããªãŠã ïŒSDSïŒïŒPH5.5ïŒäžã«10
åã«åžéããã
次ã«ILâïŒæº¶æ¶²ãã10å¹³æ¹ãã€ãŒãã®äžç©ºç¹
ç¶ã«ãŒããªããžïŒåç®ååéã«ãããªã10000ã
ã«ãã³ïŒãçšããŠ600mlã®å®¹éã«æ¿çž®ãããããŠ
次ã«ã50mMé ¢é žãããªãŠã ã1mM EDTAã
0.1ïŒ SDSïŒPH5.5ïŒã«å¯ŸããŠïŒå®¹ééææ¿Ÿéããã
次ã«ãã®ææã5ÎŒïœSDSïŒmlãå«æãã10mMãª
ã³é žãããªãŠã ã«å¯ŸããŠãæ®çSDSã131ÎŒïœ
SDSïŒmgèçœè³ªã®å€ã«éãããŸã§ããã«éææ¿Ÿé
ãããçŽ255mgã®ILâïŒã0.6mgïŒmlã®æ¿åºŠã§åå
ãããïŒ425mlïŒã
ç¶ã«ãŒããªããžïŒåç®ååéã«ãããªã10000ã
ã«ãã³ïŒãçšããŠ600mlã®å®¹éã«æ¿çž®ãããããŠ
次ã«ã50mMé ¢é žãããªãŠã ã1mM EDTAã
0.1ïŒ SDSïŒPH5.5ïŒã«å¯ŸããŠïŒå®¹ééææ¿Ÿéããã
次ã«ãã®ææã5ÎŒïœSDSïŒmlãå«æãã10mMãª
ã³é žãããªãŠã ã«å¯ŸããŠãæ®çSDSã131ÎŒïœ
SDSïŒmgèçœè³ªã®å€ã«éãããŸã§ããã«éææ¿Ÿé
ãããçŽ255mgã®ILâïŒã0.6mgïŒmlã®æ¿åºŠã§åå
ãããïŒ425mlïŒã
222mgã®ã¿ãã次ã®ããã«è¡ã€ã補å€åã®ãã
ã«çšããïŒ370mlã®ILâïŒæº¶æ¶²ïŒ222mgã0.6mgïŒ
mlïŒã10mMãªã³é žãããªãŠã ïŒPH7.5ïŒåã³20
ïŒ ãã³ãããŒã«ã«ããåžéããŠæçµæ¿åºŠã次ã®ã
ãã«ããïŒ 0.25mgïŒmlILâïŒ ïŒïŒ ãã³ãããŒã«10mMãªã³é žãããªãŠã ïŒPH7.5ïŒäž 次ã«ããã®æº¶æ¶²ã0.2ãã¯ãã³ãã€ã«ã¿ãŒãé
ããŠç¡èæ¿Ÿéããç¡èãã€ã¢ã«ïŒ1.2mlå 填容éïŒ
ã«å å¡«ãããããŠåçµä¹Ÿç¥ããã
ã«çšããïŒ370mlã®ILâïŒæº¶æ¶²ïŒ222mgã0.6mgïŒ
mlïŒã10mMãªã³é žãããªãŠã ïŒPH7.5ïŒåã³20
ïŒ ãã³ãããŒã«ã«ããåžéããŠæçµæ¿åºŠã次ã®ã
ãã«ããïŒ 0.25mgïŒmlILâïŒ ïŒïŒ ãã³ãããŒã«10mMãªã³é žãããªãŠã ïŒPH7.5ïŒäž 次ã«ããã®æº¶æ¶²ã0.2ãã¯ãã³ãã€ã«ã¿ãŒãé
ããŠç¡èæ¿Ÿéããç¡èãã€ã¢ã«ïŒ1.2mlå 填容éïŒ
ã«å å¡«ãããããŠåçµä¹Ÿç¥ããã
ããããŠè£œé ããã補å€ã¯ããã«ãããŠèšåºç
ã«äœ¿çšããããããŠé£ç¶éèå æ³šå ¥ãšããŠæäžã
ããå ŽåïŒçŸäžãŠãããïŒm2ãŸã§ã®æäžã«ãããŠ
èš±çšãããåã¯éèå ãããã¯çèå ãã«ã¹
ïŒbolusïŒãšããŠæäžãããå ŽåçŸäžãŠãããïŒKg
ãŸã§èš±å®¹ããããçµæILâïŒã®äœ¿çšã«ã€ããŠã®
é©åœãªææšã«ã¯æ¬¡ã®ãã®ãå«ãŸããïŒ (1) åŸå€©çãªãå 倩çãªãåã¯ååŠççæ³ãå ç«
çæ³ãããã¯ç §å°ã«ããèªå°ãããå ç«äžå šç¶
æ ã®æ²»çïŒ (2) ãŠã€ã«ã¹æ§ãå¯çæ§ãçæ§ãçèæ§ãåçå
ç©æ§ãåã¯ãã³ãã¯ããªãŠã æ§ãããã¯ãã®ä»
ã®æææ§çŸæ£ã®çæ³ã«ããã现èæ§å ç«å¿çã®
å¢åŒ·ïŒ (3) æææ§ãçæ§ããªãŠããæ§åã¯èªå·±å ç«æ§çŸ
æ£ã®æ²»çã«ããããšããœãŒããïŒex vivoïŒã§
ã®çŽ°èã®å¢åŒ·ãããå¿çã®èªå°ïŒ (4) ãªãŠããã€ãåã¯ä»ã®ççæ§é¢ç¯ççã®æ²»
çïŒ (5) ç°åžžå ç«å¿çã®çŸæ£ãäŸãã°å€çºæ§ç¡¬åçã
å šèº«æ§çŽ ææ§çŒç¡ã糞çäœè çãåã¯èçã®æ²»
çïŒ (6) é è¡ç³»è «çãåã¯é è¡çµç¹ã®åçæ§ãããã¯
åçäžè¯æ§ç°åžžã®æå¶ïŒ (7) 倩ç¶ã«ååšãããæäžããã倩ç¶ã®ãååŠç
ã«åæãããã¯ä¿®é£Ÿããããåã¯çµç¹æäœã«ã
ãã¯ã¯ãã³ããããã¯å»çç®çã«æäžãããä»
ã®ãæåã«å¯Ÿãã现èæ§åã¯æ¶²æ§å¿çã®èªå°ã«
ãããã¢ã·ãŠãã³ããšããŠã®äœ¿çšïŒ (8) ç¥çµäŒé調æŽå€ãšããŠã®ãããã¯ç²Ÿç¥æŽ»æ§å€
ãšããŠã®ãå»çç®çã®ãšã³ã±ãã¢ãªã³ãšããŠ
ã®ãåã¯äžæ¢ç¥çµç³»æ©èœã®èª¿ç¯å€ãšããŠã®äœ¿
çšïŒ (9) äžèšã®çŸæ£ç¶æ ã®æ²»çã®ããã®å±æé©çšã«ã
ããŠïŒ (10) 现èæ¯æ§ååŠæ²»çåã¯çŽæ¥çæ³ãããã¯ã¢ãž
ãŠãã³ãç°å¢ã«ãããçæ§ãããã¯åçæ§çŸæ£
ã®æ²»çã«ãããç §å°ãããã¯æè¡ãšçµåãã
ãŠïŒ (11) çŽæ¥æãŠã€ã«ã¹æ§ãæçèæ§ãæ现èæ§ã
ãããã¯æåæ§åç©æŽ»æ§ãæããè¬å€ãšçµåã
ããŠãåã¯å žååã³éå žåm.ããã«ã¯ãã·ã¹
ã®è¬å€æ²»çãšçµåãããŠïŒ (12) ä»ã®å ç«èª¿ç¯å€ããªã³ãã«ã€ã³ïŒäŸãã°IL
âïŒãILâïŒãCSFâïŒãαâã€ã³ã¿ãŒããš
ãã³ãåã³ïœâã€ã³ã¿ãŒããšãã³ïŒã倩ç¶ã®ã
ããã¯èªå°æ§ã®æ现èæ§æ¯çŽ ãçæ§ãæææ§ã
èªå·±å ç«æ§åã¯ãªãŠããæ§çŸæ£ã®æ²»çã«ããã
æªæ§çŽ°èã®æº¶è§£åã¯éæ¢ãäžä»ããååãšçµå
ãããŠïŒãã㊠(13) æææ§çŸæ£ã«å¯Ÿããäºé²ã
ã«äœ¿çšããããããŠé£ç¶éèå æ³šå ¥ãšããŠæäžã
ããå ŽåïŒçŸäžãŠãããïŒm2ãŸã§ã®æäžã«ãããŠ
èš±çšãããåã¯éèå ãããã¯çèå ãã«ã¹
ïŒbolusïŒãšããŠæäžãããå ŽåçŸäžãŠãããïŒKg
ãŸã§èš±å®¹ããããçµæILâïŒã®äœ¿çšã«ã€ããŠã®
é©åœãªææšã«ã¯æ¬¡ã®ãã®ãå«ãŸããïŒ (1) åŸå€©çãªãå 倩çãªãåã¯ååŠççæ³ãå ç«
çæ³ãããã¯ç §å°ã«ããèªå°ãããå ç«äžå šç¶
æ ã®æ²»çïŒ (2) ãŠã€ã«ã¹æ§ãå¯çæ§ãçæ§ãçèæ§ãåçå
ç©æ§ãåã¯ãã³ãã¯ããªãŠã æ§ãããã¯ãã®ä»
ã®æææ§çŸæ£ã®çæ³ã«ããã现èæ§å ç«å¿çã®
å¢åŒ·ïŒ (3) æææ§ãçæ§ããªãŠããæ§åã¯èªå·±å ç«æ§çŸ
æ£ã®æ²»çã«ããããšããœãŒããïŒex vivoïŒã§
ã®çŽ°èã®å¢åŒ·ãããå¿çã®èªå°ïŒ (4) ãªãŠããã€ãåã¯ä»ã®ççæ§é¢ç¯ççã®æ²»
çïŒ (5) ç°åžžå ç«å¿çã®çŸæ£ãäŸãã°å€çºæ§ç¡¬åçã
å šèº«æ§çŽ ææ§çŒç¡ã糞çäœè çãåã¯èçã®æ²»
çïŒ (6) é è¡ç³»è «çãåã¯é è¡çµç¹ã®åçæ§ãããã¯
åçäžè¯æ§ç°åžžã®æå¶ïŒ (7) 倩ç¶ã«ååšãããæäžããã倩ç¶ã®ãååŠç
ã«åæãããã¯ä¿®é£Ÿããããåã¯çµç¹æäœã«ã
ãã¯ã¯ãã³ããããã¯å»çç®çã«æäžãããä»
ã®ãæåã«å¯Ÿãã现èæ§åã¯æ¶²æ§å¿çã®èªå°ã«
ãããã¢ã·ãŠãã³ããšããŠã®äœ¿çšïŒ (8) ç¥çµäŒé調æŽå€ãšããŠã®ãããã¯ç²Ÿç¥æŽ»æ§å€
ãšããŠã®ãå»çç®çã®ãšã³ã±ãã¢ãªã³ãšããŠ
ã®ãåã¯äžæ¢ç¥çµç³»æ©èœã®èª¿ç¯å€ãšããŠã®äœ¿
çšïŒ (9) äžèšã®çŸæ£ç¶æ ã®æ²»çã®ããã®å±æé©çšã«ã
ããŠïŒ (10) 现èæ¯æ§ååŠæ²»çåã¯çŽæ¥çæ³ãããã¯ã¢ãž
ãŠãã³ãç°å¢ã«ãããçæ§ãããã¯åçæ§çŸæ£
ã®æ²»çã«ãããç §å°ãããã¯æè¡ãšçµåãã
ãŠïŒ (11) çŽæ¥æãŠã€ã«ã¹æ§ãæçèæ§ãæ现èæ§ã
ãããã¯æåæ§åç©æŽ»æ§ãæããè¬å€ãšçµåã
ããŠãåã¯å žååã³éå žåm.ããã«ã¯ãã·ã¹
ã®è¬å€æ²»çãšçµåãããŠïŒ (12) ä»ã®å ç«èª¿ç¯å€ããªã³ãã«ã€ã³ïŒäŸãã°IL
âïŒãILâïŒãCSFâïŒãαâã€ã³ã¿ãŒããš
ãã³ãåã³ïœâã€ã³ã¿ãŒããšãã³ïŒã倩ç¶ã®ã
ããã¯èªå°æ§ã®æ现èæ§æ¯çŽ ãçæ§ãæææ§ã
èªå·±å ç«æ§åã¯ãªãŠããæ§çŸæ£ã®æ²»çã«ããã
æªæ§çŽ°èã®æº¶è§£åã¯éæ¢ãäžä»ããååãšçµå
ãããŠïŒãã㊠(13) æææ§çŸæ£ã«å¯Ÿããäºé²ã
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59435084A | 1984-03-28 | 1984-03-28 | |
| US594350 | 2000-06-14 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3288739A Division JPH0678239B2 (ja) | 1984-03-28 | 1991-11-05 | ã€ã³ã¿ãŒãã€ãã³âïŒãå«æããå»è¬çµæç© |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS61500790A JPS61500790A (ja) | 1986-04-24 |
| JPH0466454B2 true JPH0466454B2 (ja) | 1992-10-23 |
Family
ID=24378529
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP60501519A Granted JPS61500790A (ja) | 1984-03-28 | 1985-03-25 | 埮çç©çã«è£œé ãããã€ã³ã¿ãŒãã€ãã³âïŒãå«æããçµæç© |
| JP3288739A Expired - Lifetime JPH0678239B2 (ja) | 1984-03-28 | 1991-11-05 | ã€ã³ã¿ãŒãã€ãã³âïŒãå«æããå»è¬çµæç© |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3288739A Expired - Lifetime JPH0678239B2 (ja) | 1984-03-28 | 1991-11-05 | ã€ã³ã¿ãŒãã€ãã³âïŒãå«æããå»è¬çµæç© |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0211835B1 (ja) |
| JP (2) | JPS61500790A (ja) |
| DE (1) | DE3575072D1 (ja) |
| WO (1) | WO1985004328A1 (ja) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4569790A (en) * | 1984-03-28 | 1986-02-11 | Cetus Corporation | Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions |
| US4690915A (en) * | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| CA1297003C (en) * | 1985-09-20 | 1992-03-10 | Jack H. Nunberg | Composition and method for treating animals |
| DE3537461A1 (de) * | 1985-10-22 | 1987-04-23 | Hoechst Ag | Derivat des interleukin-2, seine herstellung und verwendung |
| JPH0645551B2 (ja) * | 1986-01-07 | 1994-06-15 | å¡©é矩補è¬æ ªåŒäŒç€Ÿ | ã€ã³ã¿âãã€ãã³âïŒçµæç© |
| US4933433A (en) * | 1986-01-31 | 1990-06-12 | E. I. Du Pont De Nemours And Company | Recombinant interleukin-2 composition and process for making it |
| US4879111A (en) * | 1986-04-17 | 1989-11-07 | Cetus Corporation | Treatment of infections with lymphokines |
| US4894227A (en) * | 1986-08-01 | 1990-01-16 | Cetus Corporation | Composition of immunotoxins with interleukin-2 |
| CA1292686C (en) * | 1986-10-27 | 1991-12-03 | Ze'ev Shaked | Pharmaceutical compositions of recombinant interleukin-2 and formulation process |
| EP0284249A1 (en) * | 1987-03-13 | 1988-09-28 | Interferon Sciences, Inc. | Lyophilized lymphokine composition |
| US4938956A (en) * | 1987-04-01 | 1990-07-03 | International Minerals & Chemical Corp. | Synergistic immunostimulating composition and method |
| US4863726A (en) * | 1987-05-29 | 1989-09-05 | Cetus Corporation | Combination therapy using immunotoxins with interleukin-2 |
| EP0315300A3 (en) * | 1987-11-05 | 1989-08-02 | Takeda Chemical Industries, Ltd. | Treatment of tuberculous and nontuberculous mycobacterial infection |
| FR2639232A1 (fr) * | 1988-10-21 | 1990-05-25 | Sanofi Sa | Medicaments contenant une interleukine-2 glycosylee |
| ZA902663B (en) * | 1989-04-07 | 1991-12-24 | Syntex Inc | Interleukin-1 formulation |
| FR2684878B1 (fr) * | 1991-12-12 | 1994-02-11 | Roussel Uclaf | Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation. |
| TW570805B (en) * | 1998-09-01 | 2004-01-11 | Hoffmann La Roche | Water-soluble pharmaceutical composition in an ionic complex |
| ES2982752T3 (es) | 2015-10-22 | 2024-10-17 | Iltoo Pharma | Composiciones farmacéuticas de il-2 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58116498A (ja) | 1981-12-28 | 1983-07-11 | Takeda Chem Ind Ltd | ïœâïŒãã³ãŒãããæ°èŠäŒä»€ïœïœïœã®è£œé æ³ |
| AU1234383A (en) * | 1982-03-17 | 1983-09-22 | Inter-Yeda Ltd. | Interferon stabilised with polyvinyl-pyrrolidone |
| DE3377363D1 (en) | 1982-03-31 | 1988-08-18 | Ajinomoto Kk | Gene coding for interleukin-2 polypeptide, recombinant dna carrying said gene, cell lines possessing the recombinant dna,and method for producing interleukin-2 using said cells |
| JPS5910524A (ja) * | 1982-07-08 | 1984-01-20 | Toray Ind Inc | ã€ã³ã¿âããšãã³çµæç©ããã³ãã®è£œé æ³ |
| IE56026B1 (en) | 1982-10-19 | 1991-03-27 | Cetus Corp | Cysteine-depleted muteins of biologically active proteins |
-
1985
- 1985-03-25 JP JP60501519A patent/JPS61500790A/ja active Granted
- 1985-03-25 WO PCT/US1985/000501 patent/WO1985004328A1/en not_active Ceased
- 1985-03-25 EP EP85901824A patent/EP0211835B1/en not_active Expired - Lifetime
- 1985-03-25 DE DE8585901824T patent/DE3575072D1/de not_active Expired - Lifetime
-
1991
- 1991-11-05 JP JP3288739A patent/JPH0678239B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE3575072D1 (de) | 1990-02-08 |
| JPH05170660A (ja) | 1993-07-09 |
| EP0211835B1 (en) | 1990-01-03 |
| JPH0678239B2 (ja) | 1994-10-05 |
| WO1985004328A1 (en) | 1985-10-10 |
| JPS61500790A (ja) | 1986-04-24 |
| EP0211835A1 (en) | 1987-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4604377A (en) | Pharmaceutical compositions of microbially produced interleukin-2 | |
| EP0268110B1 (en) | Pharmaceutical compositions of recombinant interleukin-2 and formulation processes | |
| EP0217645B1 (en) | Stable formulation of biologically active proteins for parenteral injection | |
| JPH0466454B2 (ja) | ||
| EP0206828B1 (en) | Process for recovering refractile bodies containing heterologous proteins from microbial hosts and the use thereof | |
| US5037644A (en) | Pharmaceutical compositions of recombinant interleukin-2 and formulation processes | |
| US5004605A (en) | Low pH pharmaceutical compositions of recombinant β-interferon | |
| EP0270799A1 (en) | Pharmaceutical compositions of recombinant beta-interferon and formulation processes | |
| EP0357645B1 (en) | Improved process for recovering microbially produced interleukin-2 | |
| US4931544A (en) | Succinylated interleukin-2 for pharmaceutical compositions | |
| WO1989002750A1 (en) | Pharmaceutical compositions of recombinant beta-interferon and formulation processes | |
| JPH04218000A (ja) | 修食ããªãããã | |
| CA1295087C (en) | Purification of recombinant beta-interferon incorporating rp-hplc | |
| US5643566A (en) | Formulation processes for lipophilic proteins | |
| US5066489A (en) | Combination therapy of IL-2 and DTIC for the treatment of melanoma | |
| JP2955294B2 (ja) | 埮çç©ãã粟補ãããé žåãããåçãããçµæãã€ã³ã¿ãŒãã€ãã³âïŒãååããæ¹æ³ | |
| US4999339A (en) | Combination therapy of IL-2 and DTIC for the treatment of melanoma | |
| JP3016793B2 (ja) | éå åã®éã°ãªã³ã·ã«åçµæããïœïœâ²äžïŒâŒããã®ååŸæ¹æ³ãåã³è¬ç©ãšããŠã®ãã®äœ¿çš | |
| EP2341061B1 (en) | A novel process for preparing G-CSF (granulocyte colony stimulating factor) | |
| CA1283356C (en) | Pharmaceutical compositions of microbially produced interleukin-2 | |
| WO1988001511A1 (en) | Succinylated interleukin-2 for pharmaceutical compositions | |
| BG60405B2 (bg) | ЀаÑЌаÑевÑОÑМО ÑÑÑÑавО ÐŸÑ ÐŒÐžÐºÑПбМП пÑПОзвеЎеМ ОМÑеÑлевкОМ-2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |